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1. Summary 
 
The capacity of liver to regenerate has enabled the surgical removal of large liver parts for the 
treatment of malignancy. Surgery offers the best chance for a cure from liver cancer; due to the 
ongoing shortage in donor organs limiting transplantation, hepatectomy has become the most 
frequent intervention against disease. However, the regenerative capacity of liver is not endless. While 
up to two thirds of liver can be safely removed, larger resections bear the risk of liver failure and 
subsequent death. Resection-induced liver failure (also known as the Small-for-Size Syndrome, SFSS) 
represents a major constraint for the application of surgery. The pathobiology behind the SFSS is 
poorly understood. Therefore, knowledge about the fundamental principles that limit the regenerative 
capacity of liver is needed to develop novel strategies against the SFSS.  
Liver is the central metabolic organ vital for the body. Following tissue loss, liver not only needs to 
recover mass, but must maintain essential metabolic tasks. Therefore, metabolic function needs to be 
coordinated with tissue growth during regeneration. Moreover, metabolism has to be adapted to 
provide energy for regeneration, a process that is ill-understood hitherto. SFSS liver illustrates both 
the growth-related and metabolic aspects of liver regeneration; here, liver failure is associated with a 
deficient progression through the hepatocyte cell cycle and with metabolic deficits, such as 
hyperbilirubinemia or persisting steatosis.  
Intriguingly, persisting steatosis is generally observed in situations of incomplete recovery after 
hepatectomy. Indeed, every regenerating liver transiently accumulates lipids early after tissue loss. If 
regeneration is successful, this regeneration-associated steatosis (RAS) vanishes with the major wave 
of parenchymal growth. If regeneration however fails, RAS persists such as in the SFSS. While RAS 
meanwhile is considered an essential component of regeneration, its function remains to be clarified.  
One general aim of my PhD thesis was to explore the function of RAS. The other overall aim was to get 
insight into the reciprocal control that aligns growth with the metabolic performance of liver.  
With regards to RAS, I investigated the regenerative role of PTEN, the well-known tumor suppressor 
which regulates growth and metabolism through the inhibition of the AKT-mTOR axis. In wild type 
mice, we observed PTEN downregulation at the peak of RAS after standard (68%) hepatectomy. Using 
pharmacological modulation and inducible, hepatocyte-specific Pten-/- mice, we identified PTEN 
downregulation as a promoter of cellular hypertrophy leading to a gain in functional liver mass. 
Moreover, PTEN deficiency inhibited glucose usage but enhanced the oxidation of lipids. Mild 
inhibition of β-oxidation led to the persistence of RAS and the suppression of hypertrophic growth, 
with the latter being dependent on mTOR activities. These findings indicate that PTEN downregulation 
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promotes the burning of RAS-derived lipids to fuel hypertrophic regeneration after hepatectomy. 
Therefore, one key function of RAS is to provide energy for the regenerative process.  
The role of PTEN in liver regeneration additionally highlights mechanisms that regulate tissue growth 
through the adaptation of energy metabolism. To obtain further understanding of the association 
between tissue growth and the maintenance of metabolic liver function, we investigated the 
contribution of the constitutive androstane receptor (CAR) to the regenerative process. CAR is a 
xeno/endobiotic sensor that upon activation induces the transcription of genes required for substance 
detoxification/metabolism. Intriguingly, strong CAR activation causes spontaneous hepatomegaly in 
mice, suggesting a coupling of CAR's metabolic function to regenerative capacities. Using Car-/- mice, 
CAR activators and knockdown approaches, we demonstrated that CAR activation is required to push 
hepatocytes through mitosis via the induction of the cell cycle molecule FOXM1. If the CAR-FOXM1 
axis fails, mice are prone to liver failure after hepatectomy and display all typical SFSS features. 
Importantly, we observed failed induction of CAR also in human SFSS liver, with CAR stimulation 
promoting proliferation in ex vivo human liver slices. Finally, exogenous CAR activation rescued mice 
from lethal liver failure and normalized the SFSS phenotype in a way dependent on FOXM1. The 
normalization of metabolic deficiencies via a cell cycle molecule illustrates the requirement for 
sufficient liver mass to maintain metabolic function.  
In conclusion, PTEN and CAR function in liver regeneration to coordinate tissue growth with energy 
metabolism and metabolic capacity, respectively. While metabolism feeds liver growth via PTEN, liver 
growth feeds metabolism via CAR. Importantly, both the inhibition of PTEN and the activation of CAR 
are able to rescue mice from lethal forms of resection-induced liver failure. Pharmacological 
modulation of these proteins might hence provide opportunities to mitigate the SFSS in the clinic. No 
treatment currently exists for the SFSS, and his entity remains the leading cause of death due to liver 
surgery. 
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2. Zusammenfassung 
 
Die Fähigkeit der Leber, nach Gewebeverlust zu regenerieren, hat chirurgische Eingriffe bei grossen 
Tumoren ermöglicht. Die Chirurgie eröffnet die besten Chancen für eine kurative Therapie eines 
Leberkrebses. Der sich verschärfende Organmangel limitiert die Anwendung der Transplantation, 
sodass die Resektion die häufigste chirurgische Intervention bei malignen Erkrankungen darstellt. Die 
regenerative Kapazität der Leber ist jedoch begrenzt. Während eine Resektion von zwei Dritteln der 
Leber toleriert wird, ist die Entfernung von grösseren Teilen des Organs mit der Gefahr eines 
möglicherweise letalen Leberversagens verbunden. Dieses Leberversagen, auch ‘Small-for-Size 
Syndrome’ (SFSS) genannt, ist eine ernstzunehmende Komplikation und muss bei der Planung des 
Eingriffes berücksichtigt werden. Die Pathophysiologie des SFSS ist ungeklärt. Deshalb ist ein 
umfassendes Verständnis der Vorgänge, welche die Leberregeneration fördern oder hemmen, 
notwendig, um Strategien zur Vermeidung dieses Syndroms zu entwickeln. 
Die Leber ist das zentrale metabolische Organ und übernimmt dabei lebenswichtige Funktionen. Nach 
Gewebeverlust muss die Leber nicht nur nachwachsen, sondern auch essentielle metabolische 
Funktionen aufrechterhalten. Deshalb müssen Wachstum und metabolische Funktionen während der 
Regeneration koordiniert werden. Zudem muss der Metabolismus so adaptiert werden, dass 
genügend Energie für die Regeneration zur Verfügung gestellt wird. Dieser Prozess ist bis anhin kaum 
verstanden. Die durch SFSS beeinträchtigte Leber illustriert sowohl die Wachstums-abhängigen wie 
auch die metabolischen Grenzen der Leberregeneration; einerseits ist Leberversagen charakterisiert 
durch eine verhinderte Zellteilung, andererseits durch metabolische Defizite, wie z.B. 
Hyperbilirubinemie und persistierende Steatose. 
Interessanterweise wird persistierende Steatose bei allen Formen einer Leberregenerationstörung 
beobachtet. In der Tat, jede regenerierende Leber durchläuft eine Steatose, welche sich vor der 
maximalen Wachstumswelle wieder auflöst. Kann diese Wachstumswelle nicht abgeschlossen werden 
- wie bei SFSS - bleibt die Steatose bestehen. Mittlerweile ist klar, dass diese Regenerations-assozierte 
Steatose (RAS) notwendig für den Lebernachwuchs ist, aber deren genaue Funktion noch 
unverstanden ist.    
Das Ziel dieser Arbeit war, einerseits die Funktion von RAS zu erforschen, und andererseits die 
Koordination von Wachstum und Metabolismus während der Leberregeneration besser zu verstehen. 
In Bezug auf RAS haben wir die Rolle von PTEN, einem bekannten Tumorsuppressor, untersucht, 
welcher Wachstum und Metabolismus durch die Inhibition des Akt-mTOR Signalweges reguliert. Nach 
einer Standardhepatektomie (68%) haben wir in Wildtyp-Mäusen eine Reduktion von PTEN während 
der RAS-Phase beobachtet. Mittels pharmakologischer Eingriffe und genetisch modifizierter Mäuse, 
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bei welchen Pten induziert nur in Hepatocyten ausgeschaltet werden kann, konnten wir nachweisen, 
dass die Reduktion von PTEN zu einer hypertrophen Reaktion mit Zunahme von funktioneller 
Lebermasse führt. Weiter reduzierte sich der Verbrauch von Glucose, während die Verbrennung von 
Fetten anstieg. Eine milde, pharmakologische Inhibition der -Oxidation führte zu einer verlängerten 
RAS-Phase begleitet durch eine Reduktion im hypertrophen Wachstum, welches abhängig von mTOR 
war. Diese Experimente zeigen, dass eine Reduktion von PTEN zur Metabolisierung der akkumulierten 
RAS-Lipide führt und damit das Wachstum nach Resektion fördert. Demzufolge ist RAS eine wichtige 
Energiequelle, welche notwendig für eine erfolgreiche Regeneration der Leber ist. 
Die Rolle von PTEN in der Leberregeneration illustriert Mechanismen, welche Gewebewachstum durch 
eine Adaption des energetischen Metabolismus fördern. Andererseits muss auch die metabolische 
Funktion der regenerierenden Leber aufrechterhalten werden. Um dies besser zu verstehen, haben 
wir die regenerative Rolle des ‘Constitutive Androstane Receptor’ (CAR) untersucht. CAR ist ein Sensor 
für Xeno/Endobiotika und induziert Gene, welche für die Metabolisierung verschiedenster Substanzen 
benötigt werden. Interessanterweise induziert der voll-aktivierte CAR eine Hepatomegalie, d.h. er regt 
das Wachstum der Leber in der Abwesenheit von jeglichem Gewebeverlust an. Das impliziert eine 
Koppelung von Wachstum und Metabolismus. Mittels CAR-defizienten Mäusen (Car-/-), CAR 
Aktivatoren und mRNA Interferenz Experimenten konnten wir zeigen, dass CAR für das Abwickeln des 
vollständigen Zellzyklusprogramms notwendig ist. Nach einer Hepatektomie aktiviert CAR dabei die 
Mitose durch ein wichtiges Zellzyklusmolekül genannt FOXM1. Wenn die CAR-FOXM1 Achse anch 
einer Hepatektomie nicht induziert wird, entsteht ein Leberversagen mitsamt den klassischen SFSS 
Symptomen.  
Auch in der menschlichen Leber von SFSS Patienten beobachteten wir eine fehlende CAR Aktivierung, 
und konnten die proliferative Funktion von CAR in menschlichen ex vivo Leberschnittkulturen 
nachweisen. Schlussendlich konnten wir zeigen, dass eine pharmakologische CAR Aktivierung Mäuse 
von tödlichem Leberversagen retten kann, und zwar wiederum in einer FOXM1-abhängigen Weise. 
Diese Erkenntnisse unterstreichen, dass eine Wiederherstellung der zentralen metabolischen Funktion 
der Leber auf genügend Lebermasse angewiesen ist. 
Zusammenfassend zeigt diese Arbeit, dass PTEN und CAR Schnittstellen sind, welche das 
Leberwachstum mit dem Energiemetabolismus respektive der metabolischen Leberfunktion während 
der Leberregeneration koordinieren. Währen der Metabolismus das Leberwachstum via PTEN fördert, 
unterstützt das Wachstum die metabolische Leberfunktion via CAR. Interessanterweise kann sowohl 
die Inhibition von PTEN als auch die Aktivierung von CAR Mäuse vor tödlichen Formen des SFSS 
schützen. Pharmakologische Beeinflussung dieser Proteine könnte daher in der klinischen Situation 
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Abhilfe für ein sich präsentierendes SFSS schaffen. Bis anhin gibt es keine Behandlung dieses 
Syndroms, welches nach wie vor die häufigste Todesursache nach einer Leberoperation darstellt. 
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3. Introduction 
3.1 Liver  
The liver is both: the largest internal organ and gland in the human body. Located in the upper 
abdominal cavity, it carries out a wide range of vital functions. Two main vessels supply the liver with 
blood; the hepatic artery supplies oxygenated blood, while the portal vein provides mesenteric blood 
drained from the entire gastrointestinal tract including spleen and pancreas, thus blood rich in 
toxins/nutrients but poor in oxygen. The branches of the portal vein, the hepatic artery unite with 
hepatic bile ducts to form structures known as portal tracts, which permeate the entire liver tissue. 
De-oxygenated blood flows into central vein of each lobule. The central veins converge into hepatic 
veins, which finally drain into the inferior vena cava. The unique vascularization is required for liver to 
perform its tasks, the clearance of harmful metabolites and the production of digestive bile. 
Moreover, liver produces proteins for blood plasma, hormones and cholesterol, participates in 
immune responses and contributes to blood coagulation. Finally, liver stores glycogen, is the main 
provider of bodily glucose, and is able to synthesize fatty acids, triglycerides and lipoproteins for 
transport across the body. In simple words, liver is the metabolic center of the body.  
 
Figure1. Structure of liver acinus and sinusoid. Adapted from [1]. 
Liver parenchyma is the main contributor to hepatic mass and consists of highly differentiated 
epithelial cells, the hepatocytes [HEPs].  HEPs are closely associated with the hepatic blood flow, with 
each HEP lining a liver sinusoidal endothelial cell [LSECs]. LSECs form the sinusoids, which further are 
populated with liver-resident macrophages, the phagocytic Kupffer cells. Blood flows into sinusoids 
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from the terminal branches of the portal vein and hepatic artery, and then is drained into the terminal 
hepatic veins. The Space of Disse is defined as the interface between LSECs and HEPs. It is rich in 
extracellular matrix and hosts stellate cells as well as dendritic cells. As a special feature, LSECs have 
fenestrated membranes, enabling efficient exchange between HEPs and blood, a key requirement for 
proper liver function. Altogether, the sinusoid and its surrounding cells form the hepatic acinus - the 
functional unit of the liver (Fig.1). 
3.2 Liver regeneration 
The vital function of liver renders it indispensable for life. Moreover, the chronic exposure of liver to 
toxins has its toll. The liver hence is equipped with a unique ability to regenerate, ensuring lasting 
function throughout the organismal life span. Rapid recovery until original volume happens. Following 
significant tissue loss (up to 70% of liver volume), liver regains its original volume within 2-3 weeks in 
human, and about one week in mouse. The standard mouse model for the study of liver regeneration 
is 70% partial hepatectomy [sHx]. First presented in 1931 by Higgins&Anderson, sHx takes advantage 
of the multilobular structure of rodent liver and enables tissue removal without introducing injury that 
may cause inflammation and necrosis [2]. Besides resection, toxic liver damage also can trigger a 
regenerative response. However, regeneration of an injured liver occurs different from sHx, in that it 
strongly depends on the regrowth from stem cells [3]. Recovery of liver from toxic insults will hence 
not be covered here.  
General principles of liver regeneration 
Following sHx, liver regenerates via both enlargement and synchronized division of differentiated 
hepatocytes. The major mitotic wave in mice is observed around 48 hours after sHx. The regenerative 
process is tightly regulated, and the changes that occur within the first 2 days after liver resection are 
decisive for a successful completion. LSECs, the largest non-parenchymal population, enter 
proliferation after the major parenchymal growth phase, while the repopulation of other non-
parenchymal cells is less defined. Notably, during these first two days, liver accumulates significant 
amounts of fat, which are thought to originate from peripheral adipose stores and vanish again 
around the peak of parenchymal growth. This transient lipid accumulation meanwhile is recognized as 
an obligate component required for successful regeneration. Although its function is unclear, lipids 
conceivably might serve to fulfill the demands of a growing tissue for energy and building material.  
Despite the fact that liver regeneration [LR] has been extensively studied in the past, knowledge about 
universal signals launching the regenerative response upon resection is missing. Likewise, how liver 
manages to restore its volume while proceeding with metabolic activity remains unresolved. Finally, 
the termination process is poorly understood.  
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However, a pleiad of mechanisms crucial for the entry of hepatocytes into and their further 
progression through the cell cycle has been identified. Together, these observations portray a picture 
where the precise orchestration of molecular and biochemical events - rather than the activation of 
individual pathways - enables rapid recovery of functional liver weight following resection.  
Liver regeneration and its different phases 
In general, LR comprises several phases that may be timely categorized as follows: 1) the priming 
phase includes early events that prepare HEPs to enter into cycle; 2) during the initiation and 
progression phase, HEPs enter the cell cycle and proceed through mitosis; 3) the subsequent 
angiogenic phase is defined by the reconstitution of LSECs to the revascularize the rapidly growing 
tissue; and 4) the termination phase, which starts with the angiogenic phase and basically ends with 
the re-establishment of the original liver volume [4-6]. 
Priming phase. It is a common belief that 70% resection causes significant hemodynamic changes, 
which immediately affect the liver remnant and trigger the regenerative response. Because the portal 
blood inflow continues without change upon resection, the 30% remnant suddenly receives the triple 
amount of portal blood with according changes in blood pressure. On the other hand, arterial supply is 
diminished proportional to the volume loss; it hence has been proposed that the surplus of O2-poor 
blood causes early hypoxia that then might unleash regenerative mechanisms. However, a recent 
study from our laboratory could not establish early hypoxia to play a role [7]. Better evidence exists for 
blood pressure-associated increases in shear stress, with sinusoidal KLF2 as a shear sensor that 
induces eNOS to mediate EGFR-dependent HEPs proliferation [8-10]. Further, LSECs provide mitogenic 
WNT2 to induce early β-catenin nuclear translocation in HEPs, with β-catenin activating the urokinase 
system in addition to its proliferative function [11-15]. Activation of urokinase (occurs within 5 min 
after hepatectomy and may as well be a result of sheer stress) and then matrix metalloproteinases is 
thought to cause matrix remodeling to enable the restructuring of liver tissue - but also to release 
matrix-bound HGF, thereby augmenting its local availability [16, 17]. Further contributions to HGF 
come from endothelial and stellate cells [18, 19]. At this time various cytokines derive from adjacent 
cells to HEPs (e.g Hedgehog, CXCRs [20],  β-PDGF[21]). Given the enhanced inflow of portal blood, 
availability of serum growth factors per hepatocyte rises and this may as well affect LR (Insulin [22, 
23], norepinephrine [24], serotonin [25], bile acids [26]).  
Overall, the EGFR-ligands/HGF-MET are considered core drivers of parenchymal regeneration. These 
signaling axises were classified as a complete mitogens, meaning activation of these signals induces 
proliferation in a primary HEPs culture and results in liver enlargement, when applied to the intact 
animal [5]. Deregulation of single of these pathways following sHx leads to diminished G1>S and G2>M 
transitions, and often reduced G1 entry. More so, in the case of concurrent deficiency in both 
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pathways, liver fails to regenerate [27]. The other cytokines and growth factors are considered to play 
auxiliary roles, such as in controlling the precise timing of transcription factors essential for 
proliferation, or in enhancing the effects of the HGF-MET / EGF-EGFR pathways (Fig.2). Deficiency in 
one of these auxiliary factors usually leads to some regenerative delay, but is compensated through 
pathways with redundant function.  Indeed, redundancy is a fundamental principle in LR, ensuring 
successful regeneration also under subopitmal conditions [5]. 
Initiation and progression. Under influence of mitogenic signals, received from adjacent cells and 
bloodstream multiple intracellular pathways become active (e.g. ERK1/2, NFkappaB, SMAD). Further 
activation of key transcription factors is ensured via several mechanisms. Thus, the activation of STAT3 
crucial for G1 entry, is triggered via EGFR-ligands/HGF-MET as well as IL6/TNFa derived from Kupffer 
cells (Fig.2) [28-31]. Induction of transcription factors STAT3, NFkappaB and AP-1 causes significant 
alterations in HEPs gene expression patterns [6]. Many of those relate to the cell cycle, particularly 
overexpression of cyclin D marks definite G1 entry and is thought to be the “point of no return”. Then 
proper G1>S and G2>M transitions depend on activation of diverse mitogenic pathways as well as their 
correct extent and timing. The majority of these converge on the transcription factor FOXM1, a key 
promoter of the S/M-phases and a repressor of the cell cycle inhibitor P21 in hepatocytes [32].  
Hepatocyte proliferation starts in the periportal areas (zone 1) and then proceeds to the pericentral 
areas (zone 2&3) (Fig.2) [33]. Interestingly, although almost all HEPs enter the S-phase, 15% never 
complete the division [33]. Moreover, resent studies are questioning the established hyperplasia-
dependent model of LR, because proliferation alone is not sufficient to recover the original liver mass. 
Rather, hyperplasia has been proposed as a core mechanism behind volume increase, given that a 
rapid increase in HEP size is observed within day 1 after hepatectomy [34, 35]. Hypertrophy might be 
an early compensatory response to immediately support tissue function and body homeostasis 
following tissue loss. Although requiring additional research, HEP enlargement seems to be mediated 
via the AKT/mTOR pathway, activated shortly after hepatectomy [34].  
Angiogenic phase. Since LSECs are the first affected after hepatectomy, angiocrine signaling is pivotal 
for induction of parenchymal regeneration. Down-regulation of endothelial ANG2 leads to reduced 
production of TGFb1 (key inhibitor of HEPs proliferation) by LSECs, unleashing HEPs proliferation while 
LSECs themselves remain quiescent [36]. To launch HEPs into the cell cycle, HGF previously bound to 
extra-cellular matrix becomes available due to tissue remodeling. The regenerative stimulus is 
amplified via HGF and WNT2 produced by endothelial cells in VEGF/VEGFR1/2 –dependent manner 
[37]. Moreover, VEGF stimulates parenchymal proliferation also via hepatocellular VEGFR1 
engagement [37]. Furthermore, VEGF released in the bloodstream recruits to the liver bone marrow 
derived progenitor cells of LSECs (BM SPCs) [38], that are rich in HGF [39] (Fig.2).  
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While growing parenchymal mass, liver develops hypoxia. HEPs induce a hypoxic response via HIF2a, 
which has a dual function. It promotes progression of the HEPs through the mitosis, and 
simultaneously induces Vegf gene expression, leading to the major wave of VEGF, essential for 
subsequent angiogenic phase [7]. Simultaneously re-elevated ANG2 upregulates TGFb1 to decline 
HEPs proliferation after mitotic peak [36]. Among BM SPCs, resident progenitor cells or LSECs, BM 
SPCs are considered to be major contributors to the restoration of sinusoidal vasculature as 
progenitors of LSECs [40, 41]. Complex angiogenic process starts at day 4 after hepatectomy in mice 
and will be completed within next 3-4 days [9]. Crosstalk between LSECs and HEPs described here is a 
notable example of mutual intercellular coordination, which assures highly ordered and efficient 
process of LR (Fig.2). 
Termination. Termination of liver regeneration is the least understood phase. Upregulation of TGFb1 
clearly is an important signal for HEPs to cease their proliferation. The remodeling of the extracellular 
matrix occurring early after sHx contributes to TGFb1 regulation as it releases ECM (extracellular 
matrix) bound active TGFb1 into plasma, where it gets inactivated by absorption through alpha-2-
macroglobulin [42-44]. Over time, when the wave of pro-regenerative factors is declining, and when 
sinusoidal repopulation enables the reconstruction of a more ordered liver architecture, the ECM is 
being rebuilt by stellate cells. Ongoing with rebuilding, more and more of newly synthesized TGFb1 
gets rebound to the ECM, re-establishing a state of hepatocellular quiescence as it occurs in resting 
liver [45-47]. Besides TGFb1, the reconstruction of the ECM also relocates in close proximity to HEPs 
decorin, which counteracts the key mitogenic pathways downstream of MET and EGFR [48-51]. 
Moreover, ECM ties down free HGF to inactivate it. Finally, ECM remodeling leads to upregulation of 
ILK and GCP3, which - through ill-defined paths likely involving Yap signaling contribute to termination 
of LR [52, 53]. 
There is evidence indicating some exaggeration of the regenerative response leading to overgrowth. 
Eventually, the number of HEPs is larger than in the original liver. This number is re-adjusted by a small 
wave of apoptosis eliminating excess HEPs. This process perhaps is regulated by dynamic contributions 
of MST1/2-YAP1 pathway, famous for its function in organ-size control [54, 55]. Nuclear YAP1 
promotes proliferation, anti-apoptosis and “stemness” [56]. It is negatively controlled by MST1/2 
kinase which targets YAP1 for degradation [57]. By day 1 after hepatectomy the activity of MST1/2 
kinase is attenuated, resulting in elevated YAP1 activity and its downstream targets. When the original 
liver-to-body weight ratio is restored, MST1/2 activity rises back to the baseline level and stops YAP1 
action [54]. In common agreement, the downregulation of YAP1 is considered to be an endpoint event 
in the termination of regeneration also through the induction of the apoptotic wave.  
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Figure 2. Liver regeneration from three different perspectives. (A) Structure of the liver lobule. Zone 1 
hepatocytes (periportal; closest to portal vein) proliferate first after sHx, whereas zone 2 hepatocytes 
contribute to the second and third proliferative peaks. (B) Key intracellular signaling pathways in 
hepatocytes after PH. Adapted from [58] with modifications . (C) In the intact liver, HEPs are 
mitotically quiescent. LSECs secrete TGFb1, which acts as a proliferation brake on HEPs. Following sHx, 
LSECs downregulate ANG2 and TGFb1 during the early phase of regeneration, though ANG2 is 
expressed in the later angiogenic phase, during which it activates VEGFR2 and TIE2 signaling. 
Endothelial cells provide HGF and WNT2 and the cytokines CXCR7 and CXCR4, stellate cells - HGF and 
Kuppfer cells - IL6. These factors act with circulating factors, e.g EGF to stimulate HEP proliferation. 
Proliferation of LSECs, hepatic macrophages and stellate cells occurs later. Adapted from [20] with 
modifications. 
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However, akin to the signals that are needed for the initiation of LR, a combination of various events is 
likely needed for a proper termination of liver regrowth. The decline in pro-mitogenic factors will add, 
but signals of a broader nature are likely to contribute, such as systemic responses that sense the re-
installation of normal hepatic capacity. Recent evidence indicates regulation of termination through 
the bodily bile acid pool that liver must circulate and which obviously will relate to the actual size of 
liver, reflecting the state of hepatostat [59]. 
3.3 Regeneration, liver surgery and the associated limits 
The capacity of liver to regenerate is fundamental to liver surgery, because it enables the removal of 
large parts of liver such as for the treatment of liver tumors.  
Small-for-Size-Syndrom 
Despite major efforts in improving the management of liver tumors, surgery continues to offer the 
best chance for a complete cure. While the application of transplantation is restricted due to the 
ongoing shortage in donor organs, the resection of diseased liver parts is the most frequent 
intervention against liver malignancies. However, resection has its own limitations, with the most 
important being the extent of hepatectomy required for a complete removal of all cancerous parts. In 
healthy humans, up to 75% of liver mass can be removed without major risks [60].  Above this 
threshold, the liver remnant fails to recover. The small liver mass is unable to meet the functional 
demands of the body, with the developing liver failure putting patients at serious risks. In the clinic, 
this entity is known as Small-for-Size Syndrome [SFSS] and is the most frequent cause of death due to 
liver surgery. Therefore, SFSS is a serious factor limiting the application of liver surgery for the cure of 
malignancy.  
Deficient regeneration as a cause of the SFSS 
Why small liver remnants fail to recover is unclarified. It has been suggested that the massive increase 
in portal flow after extended hepatectomy may damage the sinusoidal lining, with persistent injury at 
the LSEC-HEP interface compromising liver function. In clinical studies, however, no clear association 
between portal pressure and the SFSS risk could be established [61, 62]. The contributions of portal 
pressure and liver injury to the SFSS hence are still under debate.  
To better understand the pathophysiology behind resection-induced liver failure, our lab has designed 
a new mouse model of the SFSS. The model is based on a modified extended 86% hepatectomy [eHx] 
designed to protect main hepatic vessels and ducts during surgery. Although mice after eHx do not 
display hepatic injury as assessed through multiple parameters, they present with features typically 
observed in human SFSS, including persistent steatosis, a reduced metabolic liver capacity, and 
increased mortality [63]. These findings therefore argue against liver damage as a requirement for the 
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SFSS to develop.  
Instead, the findings from this new SFSS model point to the simple failure of regeneration as a cause 
of the SFSS. Comparing the sHx and eHx models, no major differences were observed for the entry of 
HEPs into the cell cycle (e.g. via Ki67 and cyclin E/D levels). Following eHx, however, HEPs displayed a 
deficient progression through the S and particularly the M cell cycle phase, accompanied by an 
upregulation of the cell cycle inhibitor P21. Ablation of P21 corrected these cell cycle deficits after 
eHx, enhanced the liver weight regain, and improved both the metabolic SFSS features and survival 
[63]. Therefore, means that improve the regenerative capacity of the liver may be of clinical value with 
regards to the SFSS. For example, the forkhead transcription factor FOXM1 is a key promoter of the S 
and M phases in regenerating hepatocytes, amongst other owing to its ability to promote S/M phase 
cyclins and to  repress P21 [32].  Indeed, our lab could demonstrate a deficient induction of the Foxm1 
gene after eHx [32, 63], perhaps suggesting a crucial role of timely FOXM1 upregulation for the 
outcome of extended liver resection.  
Management of the SFSS 
No recommended treatment currently exists for the management of the SFSS. A novel strategy relies 
on functional liver support employing a type of hepatic dialysis. This bio-artificial liver device [BAL] is a 
bioreactor consisting of HEPs that are separated from blood with a semipermeable membrane. The 
membrane shall mimic fenestrated LSECs, giving HEPs access to blood-derived toxins and proteins but 
no larger objects. In this way, HEPs can perform normal liver function tasks without provoking 
immunological responses [64]. Obviously, BAL could only serve as a temporary support, either 
extending the time window for small liver remnants to regenerate, or to take over liver function until a 
transplant is available.  
On the other hand, strategies that aim at improving the regenerative capacity of liver might be better 
suited for an SFSS management. Such an approach may prevent or treat the SFSS directly, not only 
improving the outcome of patients undergoing extended hepatectomy, but extending the application 
of surgery previously deemed unresectable due to a risk of SFSS [65].  
Experimental strategies in such a direction may come from the work of Katagiri et al [66, 67]. These 
researchers observed that a distinct fraction of bone marrow-derived mesenchymal stem cells named 
Muse differentiate into liver-lineage cells (HEPs, LSECs and Kupffer cells) and contribute to tissue 
repair [66, 67]. Thus, stem cell based therapies may aid the management of the SFSS.  
Currently, the main approach is to prevent the SFSS altogether by surgical enlargement of the future 
liver remnant. The most important development here are the so-called two-staged hepatectomies, 
where in a first step healthy liver mass is enlarged (such as through the ligation of diseased liver parts, 
which then provokes compensatory liver growth of unligated parts). Following successful liver growth, 
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the second step, i.e. the resection, is then performed on the enlarged liver, leaving a remnant big 
enough to prevent SFSS development. However, these approaches require repeated intervention, 
which may affect the progression of background disease, and have a limited time window for 
application. Perhaps the most promising procedure here is ALPPS, a two-staged hepatectomy where 
the first step combines portal vein ligation with a parenchymal transection. The ligation-transection 
combination leads to a markedly accelerated volume gain, enabling the application of the second step 
within a much shorter time period [68]. Hopefully, the investigation of mechanisms underlying the 
ALPPS effects may identify new pharmacological targets that might enable the postoperative 
treatment of acute liver failure as well [69].  
Importantly however, a few molecules with the potential as therapeutic SFSS candidates are already 
known. The basic principle behind these molecules is that they trigger spontaneous hepatomegaly in 
the absence of resection upon activation, suggesting they might be used for a pre/peri-operative 
enlargement of liver size to prevent/treat the SFSS. For example, activation of the nuclear receptors 
FXR and CAR does trigger hepatomegaly [26, 70]. A growing pool of evidence indicates that these and 
related molecules have pro-regenerative functions and could have curative potential in the settings of 
marginal liver remnants. These promising therapeutic targets include such molecules as LXR, PPARs, 
PPARG, PXR or estrogen receptors (reviewed in [71]). Intriguingly, these molecules are not cytokines 
or growth factors classically implicated in LR, but nuclear receptors that are deeply implicated in the 
coordination of proliferative responses with alterations in metabolic needs.  
3.4 Metabolic control of liver regeneration 
Liver regeneration can be viewed as an adaptation to metabolic insufficiencies after tissue loss. 
Removal of 70% of the liver results in the tripling of portal flow through the hepatic remnant. This 
implies a triple exposure of the remnant not only to growth factors, but also to metabolites and toxins. 
To sense these changes, hepatocytes are equipped with an array of nuclear receptors that become 
activated upon binding to endo- and xenobiotics. When active, the receptors translocate from the 
cytoplasm to the nucleus where they act a transcription factors to induce gene expression changes 
aimed at e.g. neutralizing harmful substances.  
It is thought that these nuclear receptors also guard body homeostasis during LR. Intriguingly, many of 
these receptors appear to have a dual function: besides controlling metabolic circuits, nuclear 
receptors also regulate proliferative pathways, seemingly by translating metabolic insufficiency into 
mitotic signals.  
One of the best studied nuclear receptors is the Farnesoid X Receptor (FXR). Being the primary sensor 
of bile acids, FXR regulates genes involved in bile acids synthesis, secretion, transportation, 
conjugation and detoxification. Bile acids are produced and secreted by the liver to aid the digestive 
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function of the intestines. 95% of the secreted bile acids are reabsorbed by the liver. Following 
hepatectomy, the hepatic bile acid influx proportionally increases with the lost tissue mass, quickly 
overloading the liver with potentially toxic bile acids. The subsequent activation of FXR triggers a 
metabolic response aimed at re-installing bile acid homeostasis. Simultaneously, FXR accelerates 
hepatocellular proliferation via feedback up-regulation of FOXM1b, the hepatic key promotor of cell 
cycle progression [16, 72]. In this way, liver size is being adapted to the changed metabolic conditions 
after tissue loss. Other nuclear receptors such as PXR, CAR and RXRa (the heterodimeric partner of 
most nuclear receptors) appear to function in a similar fashion, and their roles in the regulation of LR 
are being described. An interesting member of these nuclear receptors is CAR, known for its role in 
regulating xenobiotic responses and bilirubin clearance [73, 74]. Its activation can have a massive 
effect on liver and can lead to the spontaneous doubling of liver weight in mice [75]. Therefore, CAR is 
an intriguing candidate for the improvement of outcomes after extended resection. 
3.5 Liver regeneration and energy metabolism 
The extraordinary capacity of liver to regenerate after tissue loss requires an adequate energy supply. 
Moreover, liver is a key provider of glucose. Therefore, liver resection is a formidable challenge to 
energy homeostasis. Hepatectomy immediately causes systemic hypoglycemia and the associated 
depletion of hepatic glycogen stores. These profound changes appear to trigger a systemic response, 
that is the mobilization of adipose lipid stores and their redistribution from the periphery into the liver 
[76-79]. Lipogenesis seems to play little, if any, role in the formation of RAS. Indeed, FASKOL mice 
(liver-specific fatty acid synthase knockouts) exhibit normal RAS accumulation and LR after sHx [80].  
Regeneration associated steatosis as an obligate component of liver regeneration.  
As mentioned above, regeneration associated steatosis [RAS] peaks at 16h post sHx in mice, thus 
before the major wave of parenchymal growth. If LR proceeds normally, steatosis will decline and 
disappear somewhen around 48h to 72h after resection. When regeneration is impaired, RAS seems 
to persist, such as in SFSS liver featuring impaired HEP cell cycle progression [63]. One possibility is 
that RAS persists because no functional liver mass for the processing of lipids is provided as a 
consequence to failed regeneration. Yet experimental evidences suggest that hypoglycemia and 
formation of RAS are required for successful liver regeneration to occur [81-83]. For example, dextrose 
supplementation counteracts hypoglycemia and suppresses hepatectomy-induced LR via failed 
induction of FOXM1 and upregulation of P21 [83]. Vice versa, calorie restriction has the opposite 
effects and promotes the regenerative process [84]. These findings nicely illustrate the 
interconnection between metabolic parameters and transcriptional signaling regulating liver growth 
[83].  
On the other hand, pharmacological or genetic strategies that abolish RAS accumulation have an anti-
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regenerative effect and in some instances increase apoptotic rates [76, 85-87]. In support of a RAS as 
an obligate component for successful LR, HEPs undergo remarkable changes in their expression 
patterns during the first few hours after sHx. These changes include expression of “adipogenic 
phenotype” markers, suggesting the existence of a conserved transcriptional program leading to 
adipocytic transdifferentiation of hepatocytes specifically for the formation of RAS [87, 88]. However, 
in some models of deficient RAS formation (e.g. L-Fabp-null and MTP-IKO mice) LR appeared not to be 
strongly affected [80]. Perhaps RAS was not sufficiently inhibited in these models, or it was 
compensated for through adaptive lipogenesis [89] that was upregulated in these constitutive 
knockout models, possibly in analogy to the redundant signaling pathways that ensure LR under 
suboptimal conditions. [80, 89]. In any case, the weight of evidence clearly favors RAS as a required 
component of LR [76, 86, 87]. 
Putative functions of RAS. 
 If RAS indeed is required for LR, it should have a function. Anecdotal evidence has pointed to β-
oxidation of lipids as the predominant ATP source in regenerating liver early after sHx, with the 
inhibition of β-oxidation lowering DNA synthesis [90]. Vice versa, infusion of lipids along with carnitine 
(facilitates β-oxidation via transfer of long-chain fatty acids across the mitochondrial membrane) 
accelerated the onset of HEP proliferation after sHx [91, 92]. It is hence plausible to speculate that the 
accumulation of lipids in HEPs after tissue loss serves to satisfy the energy demands of the growing 
parenchyme. Other observations support the view of RAS as an energy provider. The administration of 
adiponectin at hepatectomy promotes both β-oxidation and LR, while leptin has the contrary effect 
[87, 93]. Indeed, experimental manipulations that lead to a suppression of β-oxidation consistently 
inhibit LR but also cause the persistence of RAS [93-95], implying RAS provides the lipids that fuel 
regeneration.  
Putative signaling axes that may contribute to RAS regulation and/or turnover.  
Very little is known about molecular signaling cascades that are associated with RAS and its turnover. 
An important pathway implicated in the regulation of metabolism and cell/tissue growth is the AKT-
mTOR axis. In the heart, in skeletal muscles, and in several cancers, mTOR activity has been reported 
to promote mitochondrial fatty acid metabolism and oxidative phosphorylation [96-100]. Kenerson 
and colleagues recently demonstrated that persistent activation of mTORC1 (one of the two mTOR 
complexes) in liver speeds up β-oxidation via upregulation of CPT1A (Carnitine palmitoyltransferase 1a 
- a rate-limiting enzyme for mitochondrial lipid oxidation). By promoting lipid catabolism, mTORC1 
opposes the lipogenic effects of its upstream activating kinase AKT, thereby protecting liver from high 
fat diet-induced steatosis [101]. Notably, AKT has other metabolically active targets. AKT for example 
inhibits FOXO1, a transcription factor that is central to the regulation of gluconeogenesis, 
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glycogenolysis, and adipocyte differentiation. Notably, LR in Akt1/2-nil mice is deficient and 
accompanied by reduced glycogenesis and RAS formation; these defects can be reversed by the 
simultaneous deletion of FOXO1 [102]. Interestingly, AKT activity contributes to the regain in liver 
mass after sHx particularly through hypertrophic mechanisms [34, 103].  In more detail, PI3K - which 
receives regenerative signals directly from growth factor receptors - is a key upstream activator of AKT 
and promotes both hyperplastic and hypertrophic liver growth. Proliferation seems to be induced via 
direct activation of STAT3, while hypertrophy is dependent on AKT signaling, consistent with mTOR as 
a major regulator of cell size [34, 103]. Thus hyperplasia and hypertrophy can be dissociated at the 
level of PI3K, because the kinase can directly phosphorylate proteins (such as STAT3) but also 
phosphoinositides (most important here is the generation PtdIns(3,4,5)P3 (phosphatidylinositol 
(3,4,5)-trisphosphate)), which then activate PDK1, the upstream activating kinase of AKT. The 
phosphoinositide-dependent activation of AKT-mTOR is under negative control through PTEN, which 
thereby holds a powerful position in restricting all the metabolic and growth-related processes 
governed through AKT-mTOR. The importance of PTEN in the regulation of growth is emphasized 
through the fact that the protein is one of the most frequently mutated tumor suppressors in human 
cancers [104]. Indeed, subtle reductions in hepatic PTEN have been observed after resection, 
suggesting that PTEN alterations may contribute to the metabolic adaptations associated with the 
parenchymal growth after tissue loss.  
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3.6 GOAL AND AIMS OF THE PHD THESIS 
In summary, the above introduction portrays liver regeneration as an adaptive response, with tissue 
loss causing metabolic insufficiency, which in turn triggers the recovery of functional liver mass. 
Insufficiencies related to the reduced metabolic clearance function of the liver may be sensed through 
nuclear receptors, which activate pathways to deal with the metabolic overload, and in parallel 
promote parenchymal growth to re-install the required metabolic capacity. On the other hand, after 
tissue loss hypoglycemia inevitably develops and provokes a systemic response, including the 
redistribution of peripheral fats into the liver. The peripheral import results in the formation of RAS, 
which in turn may serve to provide the fuel for the parenchymal growth. Consequently, an impaired 
RAS turnover should counteract the regenerative capacity of liver. 
This PhD thesis was set out to explore the reciprocal regulation that coordinates metabolic pathways 
with parenchymal growth during liver regeneration. More specifically, the focus was on:  
1) The role of the nuclear receptor CAR in the promotion of hepatocellular cell cycle progression and 
its therapeutic potential in the settings of resection-induced liver failure 
2) The role of PTEN in linking regeneration-associated steatosis with the energetic needs of growing 
parenchyme  
The following two paragraphs provide a more detailed background on the central two molecules 
investigated in this thesis, namely CAR and PTEN.   
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3.7 Constitutive androstane receptor 
The nuclear receptor CAR (Constitutive Androstane Receptor) is a xeno/endobiotic sensor mainly 
expressed in liver and kidneys. Upon exposure to diverse exogenous and endogenous ligands, 
activated CAR dissociates from its cytoplasmic complex and translocates to the nucleus, where it binds 
to RXRa (its heterodimeric partner). Next, the CAR/RXRa heterodimer binds to DNA in order to activate 
expression of genes required for xenobiotic elimination. The list of known CAR targets includes genes 
encoding enzymes of the first (i.e. the cytochromes such as the well-established target Cyp2b10) and 
the second (Ugt, Sult, Gst) phases of xenobiotic metabolism [73, 105, 106]. Likewise, CAR up-regulates 
membrane transporters Bsep, Ntcp, Oatp2, Mrp3, and Mdr2, which control the uptake of xenobiotics 
by the liver and the elimination of their metabolites via the kidneys or with the bile [105, 106]. 
Moreover, CAR is also known to induce the genes required for bilirubin clearance [74].  
The specific protein structure allows CAR to interact with a wide range of substances, rendering the 
receptor an important player in the protective system of the organism. However, a particular interest 
towards CAR arose when it became evident that the molecule is involved in number of physiological 
and pathophysiological processes unrelated to metabolite clearance: gluconeogenesis, fatty acid 
metabolism, hormonal regulation, hepatocellular proliferation and hepatocarcinogenesis.  
For a long time it has been known that a single administration of the potent CAR agonist TCPOBOP 
(1,4-bis[(3,5-dichloropyridin-2-yl)oxy]benzene) results in spontaneous hepatomegaly with a doubling 
of liver weight in mice [70, 107]. Meanwhile, several pathways conducive to liver growth were shown 
to be coordinated by CAR (Fig. 3). Firstly, activation of CAR is directly involved in the transcriptional 
activation of Cyclin D1 expression required for cell cycle entry [108]. Then, CAR up-regulates the 
expression of Myc and Mdm2 [70, 75, 109]. Elevated MYC in turn enhances the expression of Foxm1, 
the essential driver of hepatocellular cell cycle progression [75]. Eventually, the increases in MDM2 
and FOXM1 lead to a down-regulation of the cell cycle inhibitors P21 and P53 through several paths 
[110, 111]. Additionally, CAR represses P21 gene expression through direct inhibition of the P21-
transcriptional promoter FOXO1 [112]. Thus, CAR stimulates various mechanisms essential for cell 
proliferation.  
Mounting evidence supports the role of CAR in mitotic progression but also cell survival. For example, 
chronic induction of β-catenin results in cell aging due to a negative feedback leading to cell cycle 
arrest. Through the suppression of cell cycle inhibitors, CAR overrules the β-catenin-associated cell 
cycle arrest and counteracts cell aging [109]. Further, activation of CAR is associated with a lowered 
maturation of microRNA-122 (the most abundant microRNA in liver) that targets E2F1 – a 
transcription factor essential for cell cycle progression [113]. Moreover, TCPOBOP-induced CAR 
activation is associated with increased levels of YAP1, which can overrule the limits to organ size if 
24  
overactive [114]. Finally, CAR promotes survival via the transcriptional induction of Gadd45b [115]. 
Unlike its function in promoting cancer cell death, GADD45B exerts together with CAR anti-apoptotic 
effects in healthy liver through reduced MKK7-mediated phosphorylation of JNK7 [116].  
The metabolic effects of CAR activation, namely decreased gluconeogenesis/lipogenesis and enhanced 
β-oxidation, were assigned to CAR's interaction with the co-activator PGC1A, eventually disrupting 
FOXO1-, HNF4A-, and PPARA-dependent signaling [117-119].  
Figure 3. Summary of pro-mitotic activities of CAR. Adapted from [120]. 
Considering the impact of CAR on hyperplasia and energy homeostasis, it seems reasonable to 
hypothesize that CAR has an important function in LR. Indeed, limited data indicated delayed liver 
regeneration in CAR-deficient mice [26]. For my thesis, we wished to establish a promoting role for 
CAR in liver regeneration, with the goal to test its exogenous activation as a means to improve 
regeneration in the settings of resection-induced liver failure (i.e. SFSS).  
To investigate the role of CAR in the SFSS development, we performed standard hepatectomies in Car 
knockout mice and assessed CAR activities after 86%-extended resection leading to liver failure in 
normal mice. According results suggested CAR deficiency as a contributing factor to the SFSS, owing to 
CAR's virtue to induce FOXM1. Using a combination of different hepatectomies, TCPOBOP-induced 
CAR activation and siRNA-mediated Foxm1 knockdown, we established the importance of the CAR-
Foxm1 axis in LR and the SFSS. Further to this, we used humanized Car mice and ex vivo human liver 
slice cultures to estimate the clinical potential of CAR activation in liver surgery.  
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3.8 PTEN and PI3K/AKT pathway 
PTEN (phosphatase and tensin homolog) is a well-known tumor suppressor famous for its ability to 
inhibit the growth-promoting AKT-mTOR pathway (Fig. 4). Because PTEN dephosphorylates PI3K-
generated PtdIns(3,4,5)P3 (phosphatidylinositol (3,4,5)-trisphosphate), it inhibits phosphoinositide-
dependent kinase 1 (Pdk1), which mediates the PI3K-dependent AKT activation upon growth factor 
stimulation [121]. Thus, PTEN controls all the downstream processes regulated by AKT-mTORC: cell 
proliferation, cell growth, renewal, polarity, migration and metabolism (reviewed in [122]). 
Accordingly, increasing evidence supports a crucial role for PTEN in the development of metabolic 
diseases and associated cancers. Intriguingly, hepatocyte-specific PTEN deficiency results in the rapid 
development of steatosis, which can progress to steatohepatitis and further to HCC [123, 124]. The 
loss of PTEN promotes pathological steatosis via enhanced lipogenesis and through an increased 
uptake of lipids [123]. Recent findings identified the transcriptional suppressor MAF1 (a FOXO1 
downstream target) as an effector molecule in PTEN loss-dependent lipid metabolism and cancer 
signaling [125]. Importantly, Pten haploinsufficiency is sufficient to impair its tumor suppressing 
activity, indicating that even minor changes in its cellular content can have major consequences [126, 
127]. 
  
Figure 4. PTEN-PI3K/AKT pathway. Adapted from [128] with modifications. 
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PTEN also appears to have a role in physiological regeneration, such as shown for the regeneration of 
axons or pancreatic β-cells [129, 130]. Recently, PTEN was proposed to be downregulated after 
hepatectomy by several microRNAs, suggesting a role also in liver regeneration [131-133]. More 
conclusive studies have documented an important function of the AKT-mTOR axis in liver 
regeneration. After hepatectomy, AKT-mTOR regulates not only cellular hypertrophy, but also has an 
impact on glycogenesis and seemingly the formation of RAS [34, 134].  
The increased activity of the AKT-mTOR axis reported in regenerating liver implies that the observed 
PTEN downregulation may be causally related to the activity changes after sHx. PTEN hence might be 
an ideal candidate to orchestrate hepatic lipid metabolism and regenerative pathways after tissue 
loss. We reasoned that a careful documentation of PTEN's role in liver regeneration may provide a 
unique opportunity to shed light onto the complex interplay between metabolic and growth-
associated mechanisms that govern tissue regeneration. The major part of my PhD thesis was 
therefore dedicated to PTEN's function in the regenerating liver. More specifically, we first assessed 
PTEN levels during LR in C57/B6 mice and estimated its function via pharamcological modulation of its 
activities. To establish PTEN's impact on LR, we employed an inducible, hepatocyte-specific knockout 
model (AlbCretg/+Ptenl/fl (PtenKO) and AlbCre+/+Ptenfl/fl (control, PtenC)). Knockout was induced shortly 
before hepatectomy to avoid interference of pre-existing pathological steatosis with the regenerative 
process. A variety of regenerative and metabolic parameters were assessed. To explore a function of 
PTEN in RAS, we measured substrate usage via indirect calorimetry and exposed regenerating control 
and knockout liver to low doses of β-oxidation inhibitors.  
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Abstract  
BACKGROUND & AIMS: Liver can recover following resection. If tissue loss is too excessive, 
however, liver failure will develop as is known from the Small-for-Size-Syndrome (SFSS). The 
molecular processes underlying liver failure are ill-understood. Here, we explored the role and the 
clinical potential of Nr1i3 (constitutive androstane receptor, Car) in liver failure following 
hepatectomy.  
METHODS: Activators of Car, various hepatectomies, Car-/- mice, humanized CAR mice, human 
tissue and ex vivo liver slice cultures were used to study Car in the SFSS. Pathways downstream of 
Car were investigated by in vivo siRNA knockdown.  
RESULTS: Excessive tissue loss causing liver failure is associated with deficient induction of Car. 
Re-activation of Car by an agonist normalizes all features associated with experimental SFSS. The 
beneficial effects of Car activation are relayed through Foxm1, an essential promoter of the hepatocyte 
cell cycle. Deficiency in the CAR-FOXM1 axis likewise is evident in human SFSS. Activation of 
human CAR mitigates SFSS in humanized CAR mice and improves the culture of human liver slices.  
CONCLUSIONS: Impaired hepatic Car-Foxm1 signaling provides a first molecular characterization 
of liver that fails to recover after tissue loss. Our findings place deficient regeneration as a principal 
cause behind the SFSS and suggest CAR agonists may bear clinical potential against liver failure.  
 
Key words: Small-for-Size Syndrome, TCPOBOP, CITCO, hepatomegaly 
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Introduction 
 
The unique ability of liver to regenerate after 
tissue loss has permitted the surgical removal of 
large liver parts and the transplantation of partial 
liver grafts. The capacity of liver to regain 
function following tissue loss however is 
limited. In mice, standard hepatectomy (sHx, 
removal of 70% volume) leads to complete 
recovery within a week[1], whereas extreme 
resection (91% removed) induces liver failure 
and death within 48h[2]. Therefore, remnant 
volume is a key determinant for successful 
recovery after tissue loss.  
The requirement for a sufficient liver volume is 
a factor significantly limiting the application of 
liver surgery. The transplantation of marginal 
liver grafts puts recipients at risk of developing 
liver failure, a clinical entity known as the 
Small-for-Size syndrome (SFSS)[3, 4]. 
Likewise, a congruent entity can be observed 
following extended hepatectomy, the most 
frequent intervention against highly prevalent 
liver tumors. In both cases, patients present with 
metabolic liver dysfunction (e.g. 
hypoalbuminemia, hyperbilirubinemia), 
persistent hepatostatosis, and an elevated 
mortality. Indeed, SFSS following liver 
resection or transplantation represents the most 
frequent cause of death due to liver surgery[3, 
4].  
Why small liver remnants/grafts fail to recover 
is incompletely understood. Following tissue 
loss, portal blood flow into remnants/grafts 
increases; an excessive elevation in portal 
pressure may damage the sinusoidal 
endothelium, eventually causing parenchymal 
injury, but its role in the SFSS remains 
controversial[5, 6]. Liver surgery often is 
performed with clamping of hepatic blood 
supply; the resulting ischemic insult (which is 
unavoidable in transplantation) is known to 
counteract liver recovery and certainly will 
impact marginal remnants[7]. Likewise, the 
accrual of injury has repeatedly been proposed 
to account for resection-induced liver failure in 
the absence of ischemia[8-10]. However, 
hepatectomies in mice are technically 
challenging and per se may augment liver 
injury[11]. To avoid confounding by surgical 
damage, we have introduced in mice a modified 
version of extended hepatectomy (eHx, 86% 
removed) that induces little injury as assessed by 
diverse parameters[1]. Despite the absence of 
significant injury, mice following eHx display 
metabolic liver dysfunction, hepatosteatosis and 
an elevated mortality akin to human SFSS[1]. 
Therefore, injury is not required for liver failure 
to develop after extended tissue loss in mice.  
Our experimental SFSS model further was 
associated with delayed regeneration due to 
arrest at the S and particularly M phase of the 
hepatocyte cell cycle. When repeating eHx in 
mice lacking the generic cell cycle inhibitor p21, 
liver regeneration was restored and most 
metabolic SFSS features were ameliorated, as 
was survival[1]. These improvements suggest an 
impaired regenerative capacity may suffice to 
cause SFSS.  
Regenerative deficits indeed are a consistent 
finding in models of resection- or 
transplantation-induced SFSS[8-10, 12]. The 
road to impaired hepatocyte proliferation 
however remains ill-understood, and no clear-cut 
molecular defects are known for human SFSS. 
The notion that impaired regeneration and 
metabolic dysfunction go hand in hand with a 
marginal liver volume may hint to a pathway 
that coordinates hepatocyte proliferation with 
the liver's metabolic tasks. Nr1i3 (constitutive 
androstane receptor, Car) is a nuclear receptor 
that regulates P450 cytochromes and has diverse 
metabolic functions[13], including the clearance 
of xeno/endobiotics such as toxic bilirubin[14]. 
Notably, Car activation through phenobarbital-
like agents induces spontaneous 
hepatomegaly[15]. Likewise, Car appears to be 
required for liver regeneration after 
hepatectomy[16].  
To this end, we investigated (i) whether 
disturbed Car-dependent signaling is associated 
with the development of liver failure after tissue 
loss in mice, (ii) whether putative deficits are 
relevant for human SFSS, and (iii) whether Car 
modulation may be exploited for the clinical 
management of SFSS.  
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Materials & Methods 
 
Animals 
Animals aged 8-10 weeks were kept on a 12-
hour day/night cycle with free access to food and 
water. Male wild type mice (C57BL6, Harlan) 
were used unless otherwise stated. CAR 
knockout animals (9103-M, C57BL/6-
Nr1i3tm1.1Arte) and corresponding wild type 
controls were obtained from Taconic 
Laboratories, as were humanized CAR mice 
(9101-M, C57BL/6-Nr1i3tm1(NR1I3)Arte). Due 
to local requirements, breeding was started with 
offspring from in-house C57BL6 following 
embryonic transfer.    
Animal Surgery 
Standard hepatectomies (sHx, 70%, fully 
regenerating, 100% survival) and extended 
hepatectomies (eHx, 86%, regenerative delay, 
>75% survival, SFSS model) were performed as 
reported[1]. The same surgical technique was 
applied for extreme hepatectomy (91%, 0% 
survival within 48h), except that all segmental 
portal vessels of the right, left, and middle lobes 
were ligated. Sham operation consisted of 
cholecystectomy. SFSS orthotopic partial liver 
transplantations (using 30% (v/v) grafts) were 
performed according to Tian et al.[17]. The gain 
in liver weight, a physical measure of liver 
regeneration, was expressed through the ratio of 
liver weight to body weight (LW/BW).  
Activation of mouse Car and human CAR 
 BL6 and Car knockout mice were treated with 
the murine Car agonist TCP (1,4-bis(2-(3,5-
dichloropyridyloxy))benzene, Sigma Aldrich) 
directly prior to surgery or as indicated (see 
Supplementary Figure 1A for TCP effects in the 
absence of surgery). TCP was dissolved in 
DMSO (5mg/ml), mixed with prewarmed PBS 
(final vol. 100µl) and given by oral gavage (1-
3mg/kg).  The human CAR agonist CITCO (6-
(4-Chlorophenyl)imidazo[2,1-b][1,3]thiazole-5-
carbaldehyde O-(3,4-dichloro-benzyl)oxime, 
Sigma Aldrich, C6240, dissolved in DMSO at 
5mg/ml) was i.p. injected with prewarmed PBS 
(final vol. 100µl) into humanized CAR (huCAR) 
mice at 50mg/kg directly before hepatectomy 
and then daily until harvest. For ex vivo liver 
slice cultures, 250nM TCP and 1 or 100µM 
CITCO were added to mouse and human media, 
respectively.  
Foxm1 knockdown 
siRNAs targeting Foxm1 and the controls 
Aha1and Luciferase were designed by Axolabs 
Gmbh (Kulmbach, D) and packed into company-
owned formulations designed to preferentially 
target murine hepatocytes. Formulations were 
injected into the tail vein 48 hours before 
hepatectomy. The lack of significant toxicity 
was ascertained through the assessment of liver 
injury markers.  
Immunochemistry and tissue microarray 
These techniques were performed according to 
standard protocols and are described in the 
Supplements, including a description of human 
biopsy material.  
Western Blotting 
The procedure was performed as reported[1]. 
Antibodies are described in the Supplements.  
Quantitative Real-Time Polymerase Chain 
Reaction 
Sequence amplification and data analysis were 
performed on the ABI Prism 7000 Sequence 
Detector System (PE Applied Biosystems) as 
detailed in the Supplements. If not otherwise 
stated, expression values were normalized to 
time-matched samples from sham-operated 
mice.  
Ex vivo culturing of liver slices 
Ex vivo cultures of liver slices were prepared as 
described by de Graaf et al.[18] with slight 
modifications. Liver biopsies were obtained 
from three mice (C57BL6) and one human 
subject (diagnosed with colorectal liver 
metastasis, tissue from an unaffected lobe).  
Biopsies were embedded in 10ml liquid 
(2%wt/vol) ultralow-melting-point agarose 
dissolved in Krebs-Henseleit buffer (KHB, 5mM 
NaCl, 118mM KCl, 1.1mM MgSO4·7H2O, 
1.2mM KH2PO4, 25mM NaHCO3, 2.5mM 
CaCl2·2H2O, 25mM D-Glucose, 9mM HEPES 
in ultrapure water), cut with a vibratome into 
200µm thick slices and kept in KHB. Five to six 
slices were then plated on 0.4uM inserts (30mm 
diameter, Millicell) and the residual buffer was 
removed before placing the inserts into a cell 
culture plate containing culturing medium 
(Williams E medium (+L-glutamine) 
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supplemented with antibiotics and 14mM D-
glucose (Sigma), 30nM insulin (Gibco Life 
Technologies), 100nM glucagon (Sigma), 1nM 
corticosterone (Sigma), 1nM Egf (Sigma) plus 
5% FCS. The tissue cultures were kept in a 
standard cell incubator (37°C, 5% CO2 and 95% 
humidity) and the medium was changed daily. 
Integrity of explants was assessed by HE 
staining (i.e. the presence of a nucleus and a 
normal cell structure on histology). Experiments 
were limited to 24/48h cultures due to 
inconsistent tissue integrity at later times. 
Experiments with liver biopsies from three mice 
and one human subject were run in triplicates. 
Ethical approval for the use of human biopsy 
tissue was granted by the local ethics committee 
from Zürich (KEK-ZH-Nr. 2012-01 08).  
Statistical analysis 
Data are presented as mean ±SD. Differences 
between the groups were assessed by a two-
tailed t-test assuming unequal variance. In 
general, at least 5 mice/group were analyzed. 
For survival after sHx/eHx in wt/ Car-/- mice and 
Foxm1 knockdown, 10 animals/group were 
included. For the molecular analyzes following 
siRNA knockdown, at least three mice/group 
were used. Differences were considered 
significant at P<0.05 and indicated in figures by 
an asterisk (*). Statistical analyzes were 
performed using Prism 6.0 (GraphPad).  
Study approval 
All animal experiments were in accordance with 
Swiss Federal Animal Regulations and approved 
by the Veterinary Office of Zurich. Ethical 
approval for the human sections was granted by 
the regional ethics committee (KEK-ZH -Nr. 
2012-01 08). Written consent to study tissue for 
research purposes was received from the patient 
prior to inclusion in the study.  
 
Results 
 
Car activation after eHx is defective. To assess 
Car activity following resection, we measured its 
mRNA levels, protein levels/localization and 
downstream targets following resection. 
Compared to sHx, Car mRNA induction and 
nuclear localization were impaired after eHx 
(Figure 1A, Supplementary Figure 1B). 
Likewise, the prototypical Car target 
Cyp2b10[13] and the proliferation-related 
downstream molecule Foxm1[19] were hardly 
induced (Figure 1A, Supplementary Figure 1C), 
indicating defective Car activation following 
eHx.  
Car deficiency causes an SFSS phenotype after 
sHx. Car is thought to be needed for efficient 
liver regeneration[16]. To detail its function in 
regeneration, we analyzed Car-/- mice following 
resection and compared to wild type (wt) mice 
post sHx/eHx. Although usually at 100%, 
survival after sHx in Car-/- mice was reduced to 
levels comparable to eHx in wt mice (Figure 
1B). Liver weight gain, pH3 staining, mitoses, 
and Cyp2b10 expression were decreased 
compared to wt sHx. Similarly, Foxm1 and its 
cyclin targets Ccna2/b2 were reduced, whereas 
Cdkn1a (p21, repressed by Foxm1)[20] was 
upregulated; the SFSS-associated 
hepatosteatosis (see also Supplementary Figure 
1D) and metabolic liver dysfunction 
(hypoalbuminemia, hyperbilirubinemia) were 
present (Figure 1B). Therefore, sHx in Car-/- 
mice induces a phenotype akin to eHx in wt 
mice. Together with impaired Car activity post 
eHx, these results identify Car deficiency as a 
cause of experimental SFSS.   
Car re-activation rescues from SFSS. Car 
ligands such as phenobarbital-like compounds 
induce Car activity[15]; TCP (1,4-bis(2-(3,5-
dichloropyridyloxy))benzene) is the most potent 
agent of this class, with one TCP gavage nearly 
doubling mouse liver weight within nine 
days[21]. We found TCP-induced hepatomegaly 
was accompanied by Car nuclear 
accumulation/downstream gene induction 
(Supplementary Figure 1A). To determine 
whether TCP is able to re-activate Car after eHx, 
TCP was given to mice concomitant with eHx. 
One gavage was sufficient to restore Car nuclear 
translocation (see also Supplementary Figure 
1B) and downstream gene induction. Moreover, 
TCP suppressed p21, re-elevated pH3 and 
mitotic counts, accelerated liver weight gain, and 
normalized metabolic SFSS features after eHx 
(Figure 1C). TCP lost these effects in Car-/- 
mice, confirming dependency on Car 
33  
(Supplementary Figure 2). Next, we assessed the 
impact of TCP on survival. Given that most 
mice (>75%) survive eHx-induced SFSS, TCP 
was tested in an alternative SFSS model 
featuring 0% survival (91% hepatectomy). One-
week-survival was assessed, as this is the critical 
period after hepatectomy. TCP rescued 40% of 
mice after 91% hepatectomy. When TCP was 
tested in another lethal SFSS model 
(transplantation of 30% (v/v) SFSS grafts)[17], 
it again raised survival to 40% (Figure 1D). 
These findings demonstrate that Car reactivation 
through TCP leads to a functional recovery of 
marginal liver remnants and grafts.  
Foxm1 mediates Car effects in experimental 
SFSS. TCP-induced hepatomegaly 
(Supplementary Figure 1) is paralleled by 
Foxm1 induction[19], however the dependency 
of Car effects on Foxm1 remains unexplored. On 
the other hand, sHx in Foxm1HEP-/- mice induces 
delayed progression through the S- and M-cell 
cycle phases, akin to eHx in wt mice[1, 20]. To 
determine whether Foxm1 may be associated 
with SFSS, we mimicked its deficiency by 
αFoxm1-siRNA-mediated knockdown before 
sHx. Knockdown was observed during the S and 
M phase peaks (32h and 48h, respectively, 
Figure 2A, Supplementary Figure 1E) when 
Foxm1 is maximally induced after sHx (Figure 
1A, Supplementary Figure 1C). Foxm1 
knockdown reduced proliferative parameters, 
diminished liver weight gain, and caused 
hypoalbuminemia, hyperbilirubinemia and 
hepatosteatosis (see also Supplementary Figure 
1D). Together with the compromised survival 
following knockdown and sHx (Figure 2A), 
these findings indicate a crucial contribution of 
Foxm1 deficiency to the development of SFSS. 
When knocking down Foxm1 before eHx, TCP 
lost its effects, with liver remnants remaining 
small and steatotic (Figure 2B, Supplementary 
Figure 1D). We conclude that Car activation via 
TCP requires signaling through Foxm1 to 
prevent the development of experimental SFSS.  
Human SFSS displays pathobiological changes 
akin to mouse SFSS. Human SFSS has not yet 
been investigated at a molecular level. We 
analyzed liver tissue from SFSS patients and 
those without complications after resection. 
Regenerating human livers, but not SFSS livers, 
were positive for nuclear CAR and FOXM1 
(Supplementary Figure 3). Both regenerating 
and SFSS livers expressed KI67, indicating 
hepatocytes have entered the cell cycle[1]. In 
contrast, p21 was induced whilst pH3 was hardly 
detectable in SFSS livers, consistent with 
deficient cell cycle progression. Human and 
mouse SFSS thus seem to share basic 
pathophysiological mechanisms, implying the 
activation of human CAR might prevent SFSS in 
the clinic.  
CAR activation for human SFSS. Because TCP 
has little activity towards human CAR[22], we 
examined the human CAR agonist CITCO (6-(4-
chlorophenyl)imidazo[2,1-b][1,3]thiazole-5-
carbaldehydeO-(3,4-dichlorobenzyl)oxime)[23] 
for its ability to prevent experimental SFSS in 
transgenic mice bearing a human CAR (huCAR 
mice, where mouse Car has been replaced with 
human CAR)[14]. In response to CITCO alone, 
huCAR mice developed spontaneous 
hepatomegaly (Figure 3A), albeit less 
pronounced than wt mice on TCP. In fact, 
huCAR mice following sHx displayed impaired 
regeneration accompanied by metabolic SFSS 
features and increased mortality, indicating that 
huCAR mice do not retain the full regenerative 
capacity of wt mice (Figure 3B). Nonetheless, 
CITCO improved liver weight gain, pH3 counts, 
steatosis and hyperbilirubinemia in huCAR mice 
after eHx (Figure 3C). To provide further 
evidence for the clinical benefit of CAR 
activation, we treated ex vivo cultures of liver 
slices from a patient biopsy. Similar to mouse 
liver slices on TCP (Figure 4A), CITCO 
improved histology (see also Supplementary 
Figure 4) and increased pH3 counts in human 
slices (Figure 4B). Importantly, CITCO at high 
doses also improved viability (AST, Hmgb1, 
Casp3), but was less potent than TCP. Therefore, 
CITCO mitigates liver failure in huCAR mice 
and exerts proregenerative and protective effects 
on human liver slices, suggesting CAR 
activation may be effective against human SFSS.  
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Discussion 
 
In this study, we demonstrate a vital role for the 
nuclear receptor Car in the development of liver 
failure following tissue loss. Unlike in normally 
regenerating liver, Car is not activated following 
extended resection of the liver. Standard 
hepatectomy in mice lacking Car provokes a 
phenotype akin to that seen in our SFSS model 
after eHx. A key consequence of Car deficiency 
is the failed induction of the cell cycle promoter 
Foxm1, knockdown of which is sufficient to 
induce most SFSS features following sHx. Re-
activation of Car through its species-specific 
ligand TCP normalizes all of these features, 
illustrating the importance of Car activity for the 
prevention of experimental SFSS.  
The association between Foxm1-dependent cell 
cycle deficits and the SFSS phenotype suggests 
delayed liver regeneration is the underlying 
cause of resection-induced liver failure. Foxm1 
is considered a proliferation-specific 
transcription factor also in hepatocytes[24][20]. 
Foxm1 knockdown not only induced an SFSS-
like phenotype, but also blunted the rescuing 
effects of TCP. As a limitation, only one siRNA 
against Foxm1 was used, and off-target effects 
hence cannot be excluded. However, Foxm1 
knockdown before sHx causes cell cycle defects 
similar to sHx in hepatocyte-specific Foxm1 
knockouts[20], sHx in Car-/- mice, or eHx in wt 
mice[1]. We therefore propose that delayed 
progression through the S and particularly M 
cell cycle phase is a basic cause of liver failure.  
Besides regulating Foxm1, the functions of Car 
in hepatic metabolism will add to the full 
prevention of an SFSS phenotype. Simply due to 
volume loss, marginal remnants may be 
overwhelmed by the metabolic needs posed on 
liver. Acting as a xeno/endobiotic sensor[13], 
Car may react via Foxm1 to augment liver mass, 
but also by inducing a panel of metabolizing 
enzymes, including those needed for the 
clearance of elevated bilirubin levels[14]. The 
unusual ability of Car to modulate organ size 
restraints while controlling hepatocyte 
proliferation and function[25] implies its main 
task is the coordination between liver volume, 
its metabolic capacity, and the current metabolic 
demands. These qualities, and the possibility to 
induce its activity by exogenous ligands, render 
Car an attractive candidate for the mitigation of 
SFSS in the clinic.  
For Car to be a clinically viable target, (i) human 
SFSS should display functional deficits in the 
Car axis, (ii) activation of human CAR should 
lead to similar outcomes as with mouse Car, and 
(iii) clinical situations should be amenable to 
CAR-based strategies. The alterations we 
observed in human SFSS liver were consistent 
with a deficient CAR-FOXM1 axis along with 
defective cell cycle progression. As for the 
activation of human CAR, the human agonist 
CITCO was tested in two different systems, 
huCAR mice and ex vivo human liver slices. 
Although huCAR mice have been reported to 
efficiently induce Car-dependent metabolic 
enzymes[14], the CITCO responses we observed 
(i.e. the development of mild SFSS following 
sHx, volatile CAR downstream gene expression 
patterns) suggest a subpar communication 
between human CAR and its downstream mouse 
partners, perhaps rooting in the protein structure 
considerably differing between man and mouse 
(huCAR/mCar size ratio=1.66, with 70% 
identity only in the common sequence 
(http://www.uniprot.org). These observations 
however also emphasize the need of full Car 
activity for the prevention of liver failure. 
Despite the above inadequacies, CITCO did 
mitigate SFSS in huCAR mice and efficiently 
improved liver weight gain, likely owing to the 
induction of Foxm1. Similar to TCP, CITCO 
also was able to improve the integrity of human 
liver slice cultures and promote their 
proliferation. Again, CITCO was less effective 
than TCP; unlike TCP, repeated injection of 
CITCO is required to induce a response in 
vivo[26], indicating a relatively low efficacy of 
the ligand. Novel CAR ligands with improved 
potency/stability will likely be needed to achieve 
full activation of human CAR. The effects of 
CITCO on huCAR mice and human liver slices 
however provide a proof-of-concept for the 
potential clinical utility of CAR activation.  
Apart from remnant/graft volume and the 
presence of pre-existing liver disease[3, 4], no 
clinical predictors of SFSS currently exist, 
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placing treatment over prevention. To estimate 
the therapeutic potential of Car activation, we 
applied TCP to our lethal SFSS model in a 
delayed mode (i.e. after surgery). Indeed, TCP 
maintained its beneficial effects and again 
rescued 40% of mice (Supplementary Figure 5), 
implying a therapeutic window exists for the 
rescue from SFSS. Another obstacle to clinical 
translation is the malignant potential associated 
with CAR activation. The prime indication for 
extended hepatectomies is liver malignancy, and 
Car ligands are non-genotoxic promoters of 
rodent liver tumors[27]. CAR activation hence 
might potentially increase the risk of recurrence, 
however both TCP and Car activation are 
associated with malignancy only in chronic 
settings, suggesting a single application bears 
little risk [27, 28]. No according data is available 
for human CAR, however phenobarbital 
treatment seems not to increase liver cancer 
incidence in patients[29]. To minimize risks, 
putative trails might focus on hepatectomies for 
liver cancer displaying CAR downregulation 
(Supplementary Figure 6). Given that TCP was 
likewise efficient in a model of SFSS 
transplantation, live liver donors may safely 
benefit from CAR activation, i.e. for the 
treatment of SFSS developing in donors 
following partial graft retrieval, or for a pre-
operative enlargement of donor liver size to 
enable the riskless removal of sufficient volume 
for transplantation. Finally, unlike human liver, 
mouse liver is composed of distinct lobes that 
can be resected for hepatectomy. The more 
compacted architecture of human liver however 
usually requires parenchymal transection for 
hepatectomy, causing liver injury. Although 
injury is not necessary for SFSS to develop, it 
will increase the SFSS risk. Therefore, effective 
clinical strategies could be based on a combined 
approach to promote the regenerative capacity 
(i.e. CAR) and to prevent injury. CAR activation 
itself has some protective effects, however 
adding compounds specifically targeting injury 
may be more effective[10].  
Taken together, our study identifies Car 
deficiency as a key mechanism underlying the 
development of liver failure following extended 
tissue loss, and provides the means to correct 
these deficits. The function of Car in hepatic 
regeneration points to the translational potential 
of CAR activation, creating demand for novel, 
powerful agonists of human CAR. Moreover, 
the dependency of the beneficial Car effects on 
cell cycle-associated molecules imply that liver 
failure, including many of its metabolic features, 
arise from an insufficient capacity of marginal 
remnants to regenerate, illustrating the intimate 
nexus between proliferative pathways and the 
metabolic function of liver. 
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Figure legends 
 
Fig.1. Car deficiency underlies liver failure after eHx. (A) Car gene/protein expression and 
downstream gene expression after eHx. Despite similar protein levels, Car nuclear accumulation is 
impaired after eHx. (B) sHx in Car-/- mice induces an SFSS phenotype, as evinced through the 
assessment of relevant SFSS parameters (at 48h post sHx/eHx for wt mice and post sHx for Car-/- 
mice). Note that LW/BW (liver-to-body-weight ratio) cannot be compared between sHx and eHx due 
to a different starting value. For survival, 10 mice/group were used. (C) TCP reactivates Car and 
normalizes SFSS features (shown for 48h post Hx) after eHx. TCP-induced Foxm1 re-elevation at 
32/48h post eHx is illustrated in a magnified square. (D) TCP improves survival in lethal SFSS 
models. N=5/group unless otherwise stated; *P<.05. 
 
Fig. 2. The beneficial effects of TCP in SFSS rely on signaling through Foxm1. (A) Foxm1 
knockdown before sHx provokes SFSS-like features. Control siRNAs against Luc and Aha1 (shown 
for 48h only) were used. Note the comparison to plain sHx/eHx for LW/BW, albumin and bilirubin. 
Survival following sHx was reduced by Foxm1-siRNA, reflecting compromised liver function. (B) 
Foxm1 knockdown prior to eHx abrogates the beneficial effects of TCP. In the siRNA-treated 
samples, (-) indicates a control without siRNA.  Note the small size and the pale complexion 
(typifying steatosis) of liver remnants after eHx, or eHx plus TCP following Foxm1-siRNA-
pretreatment. N≥3/group for molecular analyses, n=10/group for survival, otherwise n=5/group. 
 
Fig. 3. CITCO induces spontaneous hepatomegaly and mitigates most SFSS features in huCAR mice. 
(A) Spontaneous hepatomegaly in huCAR mice through CAR activation via CITCO as evinced 
through the assessment of SFSS parameters. Note upregulation of Cdkn1a, and the marginal elevation 
in Ccna2/b2. (B) sHx in huCAR mice induces a mild SFSS phenotype. Note the reduced LW/BW and 
survival, the high gene expression, and elevated steatosis/bilirubin in huCAR mice. (C) CITCO 
mitigates liver failure in huCAR mice after eHx. Note the improvements in LW/BW, Foxm1, Cdkn1a, 
Ccna2/b2, pH3 and bilirubin, and the lack of significant effects on steatosis and albumin through 
CITCO. N=5/group.  
 
Fig. 4. CAR activation promotes the proliferative state and the integrity of ex vivo liver slice cultures. 
(A) TCP effects in mouse liver slices cultured for 24h or 48h. TCP added to media improves liver 
histology (HE: appearance of nuclei and regular cell structure, see also Supplementary Figure 4), 
promotes nuclear pH3 positivity, accompanied by reduced supernatant levels of injury markers 
AST/Hmgb1. Staurosporin served as positive injury control. (B) CITCO effects in human liver slices. 
At 1µM, CITCO induces modest improvements in histology and proliferative markers. At 100µM, 
these effects are stronger, along with reduced apoptotic counts (Casp3) and Hmgb1 supernatant levels. 
For ex vivo culture, three slices from each three mice, and five slices from one human liver biopsy 
were analyzed.   
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Supplement 
 
- Supplementary Materials & Methods 
- Supplementary Figures 1-6 
 
Materials & Methods 
 
Immunochemistry and tissue arrays 
Immune stainings were performed on 3 µm formalin-fixed, paraffin-embedded liver sections. 
Antigenes were retrieved by boiling in citrate buffer. The following primary antibodies were used: 
Ki67 (Abcam 16667), pH3 (Abcam ab92628), p21 (BD Pharmingen 556431), Plin2 (Abcam 
ab181463), Foxm1 (Santa Cruz sc-32855) and Car (LifeSpan BioSciences LS-C30862). Secondary 
detection was done using the Ventana Discovery automated staining system and the iView DAB kit 
(Ventana Medical Systems). Immunostainings on human tissue (CAR (Santa Cruz sc-13065), P21 (BD 
Pharmingen 556431), pH3 (Abcam ab92628), KI67 (Lifescreen Ltd. CMC27531021), FOXM1 (Santa 
Cruz sc-32855) and a part of the mouse tissue stainings were performed by Sophistolab AG (Muttenz, 
CH). Ki67 and pH3 positivity was assessed by manual counting in 10 random visual fields. Biopsy 
tissue was obtained from potential living liver donors (n=5, normal liver), from hepatectomy patients 
(including resectate samples) without postoperative complications (n=7, normally regenerating liver, 
retrieved at day 7 (3), day 8 (1), day 9 (2) and day 11 (1) post surgery), and from hepatectomy patients 
that had developed SFSS (n=7, SFSS, retrieved at day 5 (1), day 7 (1), day 9 (2), day 10 (1), day 12 
(1), day 14 (1) post surgery). The clinical diagnosis of SFSS was based on the '50-50 criteria' (Balzan 
et al. The "50-50 criteria" on postoperative day 5: an accurate predictor of liver failure and death after 
hepatectomy. Ann Surg 2005;242:824-828). Tissue microarray staining for CAR (LS-C30862) was 
performed in the Institute of Surgical Pathology at the University Hospital Zürich. Histological 
analyses were performed in a blinded fashion.  
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Western Blotting 
The following primary antibodies were used: Car (Santa Cruz, sc-13065) and β-tubulin (Cell 
Signalling, 2128). 
Quantitative Real-Time Polymerase Chain Reaction 
Total RNA was extracted from 20 mg of liver tissue using TRIzol reagent (Invitrogen) and 
transcribed into cDNA using the ThermoScript reverse-transcription PCR System (Invitrogen). 
TaqMan gene expression assays for Car (Mm01283978_m1), Cyp2b10 (Mm00456591_m1), Ccna2 
(Mm00438064_m1), Ccnb2 Mm01171453_m1, Cdkna1 (Mm00432448_m1), Foxm1 
(Mm00514924_m1) and 18S rRNA internal control (TaqMan ribosomal RNA control reagents) were 
from PE Applied Biosystems; PE Applied Biosystems). The results shown represent fold induction of 
mRNA expression ± SD.  
AST, albumin, bilirubin and Hmgb1 levels 
Serum samples were obtained from the inferior vena cava before organ harvesting. AST, albumin 
and bilirubin levels were measured using a serum multiple biochemical analyzer (Dri-Chem 4000i, 
Fujifilm). Hmgb1-ELISA was from Shino Test.   
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Supplementary Figure legends 
 
Supplementary Figure 1. Supplementary information for figures 1 and 2. (A) Car activation via TCP 
induces spontaneous hepatomegaly. A single TCP administration leads to liver growth (liver-to-body 
weight ratio) and nuclear accumulation of Car accompanied by increases in pH3 counts. The elevation 
in Car activity through TCP is reflected in the induction of its downstream genes Cyp2b10 and Foxm1 
(expression normalized to vehicle-treated, time-matched samples). N=3/group; *P<.05. (B) 
Quantification of Car deficiency after eHx and its correction through TCP. N=5/group. Control 
immunohistochemistry shows Car staining in kidney (where expression is very low) and a negative 
liver control without primary antibody. (C) Foxm1 deficiency after eHx. Immunohistochemistry 
confirms deficient induction of nuclear Foxm1 protein after eHx. Three mice/group were analyzed. (D) 
Plin2 staining for confirmation of steatotic changes. Staining for Plin2, a membrane protein required 
for the formation of lipid vesicles, marks fat droplets in liver and corroborates the steatotic alterations 
seen on histology (Figs. 1&2) following sHx, eHx, and eHx plus TCP. Three mice/group were 
analyzed. (E) Efficacy and tissue-specificity of Foxm1 knockdown at the protein level. Knockdown of 
Foxm1, but not Aha1 or Luc, causes nuclear Foxm1 depletion in regenerating liver. Note the absence 
of nuclear Foxm1 expression in non-parenchymal liver cells (see also C). Although Foxm1 was also 
expressed at moderate levels in the colon and lung of mice after Hx, no expression differences were 
noted for these tissues following Aha1, Luc, or Foxm1 knockdown, suggesting that the siRNA 
formulation preferentially targets hepatocytes. Three mice/group were analyzed. 
  
Supplementary Figure 2. TCP remains without effect in Car-/- mice. (A) TCP does not induce 
spontaneous hepatomegaly in Car-/- mice. Liver weight (LW/BW) and Car nuclear expression are 
shown for day 3 following TCP (3mg/ml) gavage. Car downstream gene expression likewise is not 
induced at day 3 after TCP injection in both naive and sham-operated liver of Car-/- mice. (B) TCP 
does not improve SFSS-related parameters in Car-/- mice. LW/BW, Car immunohistochemistry, 
downstream gene expression, pH3 staining, cell cycle-associated gene expression, and metabolic 
parameters are shown for 48h post eHx. Hepatectomized wt mice with or without TCP treatment are 
included for comparison. Note the lack of differences between TCP-treated and untreated Car-/- mice. 
N=5/group; *P<.05. 
 
Supplementary Figure 3. Pathobiology of human SFSS. (A) CAR activation is deficient in human 
SFSS. CAR immunohistochemistry for normal (non-regenerating), regenerating (after hepatectomy) 
and SFSS (after extended hepatectomy) is shown. CAR nuclear positivity counts were 5±3/HPF in 
normal, 318±47/HPF in regenerating, and 54±33 in SFSS liver. Note the presence of lipid droplets in 
SFSS liver. (B) CAR-dependent processes are defective in human SFSS. FOXM1, P21, pH3 and KI67 
immunostainings are shown for regenerating and SFSS liver. Note that visualization of P21 was done 
using an alkaline-phosphatase-based red chromogenic substrate. Five and seven patients with 
regenerating and SFSS liver, respectively, were analyzed (see Supplementary Methods for patient 
details). Stainings for the same set of molecules in mouse liver after sHx (normally regenerating, n=5) 
or eHx (experimental SFSS, n=5) are shown below for comparison.  
 
Supplementary Figure 4. Histology of ex vivo human liver slice cultures treated or not with CITCO. 
Upper images: HE stains of vehicle-treated control slices show examples of liver with well-preserved 
histology in the absence of treatment. Note the absence of regular hepatocyte architecture and/or the 
paucity of well-formed nuclei. Lower images: HE stains of CITCO-treated liver slices show one 
example of liver with ill-preserved histology (left) and one with well-preserved histology (right). Note 
the more regular liver architecture and hepatocyte nuclear structure in CITCO-treated versus vehicle-
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treated slices. Further note that unlike for CITCO-treated liver, ill-preserved histology dominated over 
well-preserved histology in vehicle-treated slices.  
 
Supplementary Figure 5. Delayed TCP injection (after eHx) maintains the beneficial effects of 
concomitant injection (with eHx). Survival is shown after extreme (91%) hepatectomy normally 
leading to 100% mortality. TCP injection 3h or 9h following hepatectomy rescues 40% of mice, akin 
to concomitant injection (Fig. 1D). N=5/group; *P<.05.  
 
Supplementary Figure 6. CAR is downregulated in the majority of human HCC. CAR 
immunohistochemistry was performed on tissue arrays including formalin-fixed paraffin-embedded 
biopsies from 100 HCC and 90 non-malignant liver controls. Representative stainings are shown to the 
left. Less than 40% of HCC examined displayed nuclear or cytoplasmic CAR expression. CAR 
activation for the treatment of SFSS may be amenable to patients undergoing hepatectomies for HCC 
with downregulated CAR.  
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Abstract 
BACKGROUND & AIMS: In regenerating liver, hepatocytes transiently accumulate lipids before the 
major wave of parenchymal growth. This regeneration-associated steatosis (RAS) is required for liver 
recovery, but its purpose is unclear. The tumor suppressor PTEN is a key inhibitor of the AKT-mTOR 
axis, which regulates growth and metabolic adaptations after hepatectomy. In quiescent liver, PTEN 
causes pathological steatosis when lost, while its role in regenerating liver remains unknown. Here, we 
explored whether PTEN is linking RAS with growth during liver regeneration.  
METHODS: We studied regeneration after partial hepatectomy in wild type mice, and in liver-
specific Pten-/- mice shortly after induction of knockout. Proliferation, hypertrophy, and parameters 
related to glucose and lipid metabolism were assessed. Liver function was tested in a model of 
resection-induced liver failure. Energy substrate utilization was determined by indirect calorimetry, 
while the role of β-oxidation was probed through CPT1 inhibition.  
RESULTS: In wild type mice, PTEN was downregulated after hepatectomy and associated with RAS 
turnover and hypertrophy. Pten knockout accelerated hypertrophic regeneration, resulting in 
hepatomegaly and raising survival after lethal resection. Following hepatectomy, the shift from 
glucose to lipid usage was enhanced by PTEN loss and correlated with the disappearance of RAS. 
Mild inhibition of β-oxidation led to persisting RAS in Pten-deficient mice and abrogated hypertrophic 
liver growth, which was rapamycin-sensitive.  
CONCLUSIONS: PTEN downregulation after hepatectomy promotes the catabolism of RAS-derived 
lipids to fuel hypertrophic liver growth. These findings identify RAS as a provider of regenerative 
energy, emphasizing the need of an adequate lipid supply for successful liver regeneration.  
 
KEYWORDS: respiratory exchange ratio; peripheral fat mobilization; small-for-size-syndrome 
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Introduction 
 
Liver regrowth after tissue loss requires the 
orchestrated regeneration of all liver-resident 
cells. The functional units of liver, the 
hepatocytes, are regenerated first via both 
hyperplastic and hypertrophic mechanisms, 
followed by the reconstitution of non-
parenchymal cells such as the liver sinusoids.1,2 
Regeneration is highly efficient, with removal of 
70% of the liver leading to complete regrowth 
within a week in mice.3 The enormous growth 
rate points to the need for suitable energy 
sources that fuel liver regeneration (LR).  
Systemic metabolic changes after partial 
hepatectomy (PH) are thought to provide 
regenerative triggers, but might also serve to 
satisfy energy demands. Liver is the major 
glucose provider, and hypoglycemia inevitably 
develops when liver mass is lost. Indeed, 
hypoglycemia is an essential stimulus to induce 
regeneration.1 Moreover, hypoglycemia is 
thought to trigger a systemic response leading to 
a redistribution of lipids from the periphery into 
the regenerating liver.4 Unlike pathological 
steatosis (i.e. fatty liver disease), hepatocellular 
lipid accumulation after hepatectomy is a 
universal, physiological process that 
accompanies successful LR.4 In mouse, 
regeneration-associated steatosis (RAS) peaks 
16h after PH and then gradually declines to lean 
values by 48-72h, thus around the major wave of 
parenchymal growth.3 RAS is needed for 
regeneration, because its disruption - be it 
through inhibition of peripheral fat mobilization 
or of fat droplet formation - impairs liver 
recovery.5-7 Although first described more than 
60 years ago,8 the function of RAS remains 
unknown.   
The tumor suppressor PTEN is a key inhibitor of 
the growth-promoting PI3K-AKT-mTOR axis. 
Specifically, PTEN opposes the 
phosphoinositide-dependent activation of AKT-
mTOR through PI3K. Signaling through this 
pathway has profound impact on fundamental 
biological processes. The AKT-mTOR axis is 
considered a key regulator of cell-autonomous 
and systemic metabolism, orchestrating the 
metabolic and energetic needs with cellular 
growth also in response to altered states.9 By 
opposing AKT-mTOR activation, PTEN holds a 
powerful position, and even minor reductions in 
its activity can have serious consequences.10 The 
loss of PTEN in hepatocytes promotes lipid 
import and lipogenesis, rapidly leading to 
pathological steatosis, which then progresses to 
hepatitis and eventually cancer.11-13 The PI3K-
AKT-mTOR pathway does participate in LR, 
with interruption of this axis compromising 
recovery after hepatectomy. Intriguingly, PI3K 
seems to promote hyperplasia by 
phosphorylating STAT3, while the 
phosphoinositide-dependent AKT-mTOR axis 
stimulates hypertrophic growth.1,14 Notably, 
AKT signaling regulates many of the metabolic 
adaptations associated with regeneration after 
tissue loss.15 No direct evidence supports a role 
for PTEN in liver regeneration thus far; however 
the pro-regenerative functions of several 
miRNAs have been associated with the 
suppression of PTEN after resection.16-18 
The downregulation of PTEN16-18 suggests the 
phosphatase is liberating PI3K-mediated AKT-
mTOR activities during LR. As such, PTEN 
reductions might regulate not only parenchymal 
growth, but also adaptations to altered metabolic 
demands following tissue loss. Given the 
steatotic phenotype of resting liver lacking 
PTEN,11,12 RAS observed in regenerating liver 
might be related to the reductions in this tumor 
suppressor after hepatectomy. Furthermore, 
recent evidence indicates also catabolic roles for 
AKT-mTOR activities in hepatic lipid 
metabolism,19 perhaps implying that PTEN 
contributes to the turnover of RAS. Therefore, 
downregulation of PTEN after hepatectomy 
might serve to orchestrate tissue growth with the 
resulting energy demands. To this end, we 
explored PTEN and associated changes in 
regenerating liver. More specifically, we aimed 
at identifying the role of PTEN in liver growth 
and RAS, with the goal to shed light onto the 
function of RAS after tissue loss.  
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Materials & Methods 
Animals 
Animals aged 8–10 weeks were kept on a 12h-
day/night cycle with free food/water access. 
Male wild-type (wt) mice (C57BL/6) were from 
(Envigo, Horst, NL). Hepatocyte-specific 
inducible Pten knockout (PtenKO) animals 
(AlbCre-ERT2Tg/+Ptenfl/fl) and corresponding 
controls (AlbCre-ERT2+/+Ptenfl/fl, PtenC) were 
kindly provided by M. Foti (University of 
Geneva). PtenKO/PtenC breeding was started 
with offspring from in-house C57BL/6 
following embryo transfer. Knockout was 
induced by tamoxifen (Sigma, 100ul, 20mg/ml 
in corn oil i.p. once a day for 5 consequent days) 
and animals were operated 4 days later. All 
animal experiments were in accordance with 
Swiss Federal Animal Regulations and approved 
by the Veterinary Office of Zürich.   
Animal surgery and substances 
Partial hepatectomy (68%, PH) and 91% 
hepatectomy (a model of lethal liver failure) 
were performed as reported.20 Sham operation 
consisted of cholecystectomy. The gain in liver 
weight was expressed through the liver-weight-
to-body-weight ratio (Lw/Bw). Wortmannin (in 
10%DMSO), etomoxir (in H20) and rapamycin 
(10%DMSO) were from Sigma (Buchs, 
Switzerland), while bpV (in saline) was from 
Merck Millipore (Darmstadt, Deutschland). 
Substances were i.p. injected in 100µl volume at 
doses and times indicated in the results.  
Histological staining 
H&E, PAS and immunochemical stainings were 
performed on 3µm archived liver sections and 
Oil Red O on cryosections. Antibodies used are 
listed in Supplementary Table 1; 
immunochemistry was performed with a Dako 
Autostainer Link48 Instrument and the iView 
DAB kit (Dako Glostrup, Denmark).3,20 
Quantification of Ki67- and pH3-positive 
hepatocytes was done by blinded manual 
counting in 10 random visual fields (20x). 
Hepatocyte size 
The ratio of cytoplasmic area/number of 
hepatocyte nuclei was histologically assessed on 
H&E images taken randomly at 40x 
magnification (5 images/sample) in a blinded 
way. Threshold was applied for area 
quantification (ImageJ NIH software) to exclude 
vessels and lipid droplets. Forward scatter was 
used to measure cell size in a flow cytometer BD 
FACSCantoII (BD Biosciences, Eysins, 
Switzerland) via FACSDiva v6.1.2 software. 
Hepatocytes were isolated from liver following 
perfusion and density centrifugation as described 
(http://munin.uit.no/bitstream/handle/10037/4575/article.pd
f?sequence=1).  
Western blotting 
The procedure was performed as reported3,20 
with antibodies listed in Supplementary Table 1. 
Quantitative real-time polymerase chain 
reaction 
Total RNA was extracted from 50 mg of tissue 
using Trizol reagent (Invitrogen, Basel, 
Switzerland). qPCR was performed on cDNA 
(Thermo Script reverse transcription PCR 
System, Invitrogen) using the ABI Prism 7500 
Sequence Detector System (PE Applied 
Biosystems, Rotkreuz, Switzerland) as 
described.3,20 18S rRNA-normalized expression 
values were presented as fold induction (2-ΔCt) 
relative to time-matched sham samples, and 
relative to uninduced liver for PtenKO/C. 
Taqman gene expression assays (Applied 
Biosytems) are listed in Supplementary Table 2.  
Indirect calorimetry and Echo-MRI 
Indirect calorimetry experiments were conducted 
at the Small Animal Metabolic Phenotyping core 
facility (University of Geneva), and approved by 
the Geneva Health Head Office. Energy 
expenditure and the respiratory exchange ratio 
(RER) were derived from O2 consumption and 
CO2 production; RER differences between 
PtenKO and PtenC were assessed through AUC 
(area-under-the-curve) analysis. Locomotor 
activity was recorded by an infrared frame, and 
food/fluid intake were measured by respective 
sensors. Parameters were recorded in mice 
individually housed in Labmaster metabolic 
cages (TSE, Bad Homburg, Germany) after 5 
days of adaptation. After recording day 2, mice 
were operated, underwent Echo-MRI and were 
returned to metabolic cages for another 3 
recording days. An EchoMRI-700 quantitative 
nuclear magnetic resonance analyzer (Echo 
Medical Systems, Houston, TX) was used to 
measure total fat and lean mass. 
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Lipid and glycogen measurements 
Quantitation kits were used to measure 
triglycerides (Abcam, Cambridge, UK; 
ab65336). HDL (Sigma, Buchs, Switzerland; 
MAK045-1KT), and glycogen (Sigma; 
MAK016-1KT).  
Statistical analysis 
Data are presented as mean ±SD unless stated 
otherwise. Differences between groups were 
assessed by a two-tailed t test assuming unequal 
variance. In general, n≥5 mice/group were 
analyzed. For survival after 91%-hepatectomy, 
10 animals/group were included. Differences 
were considered significant at p<0.05 and 
indicated by an asterisk (∗). Statistical analyzes 
were performed using Prism 6.0 (GraphPad). 
 
Results 
 
PTEN is associated with RAS turnover, weight 
gain and hypertrophy in regenerating liver 
To explore the roles of PTEN and RAS, we 
assessed lipid-associated parameters and PTEN 
levels following standard (68%) hepatectomy 
(PH) in wt mice. Histology confirmed the RAS 
peak at 16h and its gradual disappearance 
around the times of major parenchymal 
growth.3,8 The steatotic peak was preceded by 
the induction of Plin2, which promotes 
hepatocyte-adipocyte transdifferentiation and is 
required for lipid droplet formation.21 Around 
the steatotic peak, Cd36 (fatty acid translocase) 
was upregulated, consistent with peripheral 
import of fat.6 Further, β-oxidation genes 
(Cpt1a, Hadha/b) were  
elevated at the expense of lipogenic genes 
(Scd1a, Acc, Fasn) (Fig. 1B), suggesting fat is 
being accumulated for energetic needs.  
Significant PTEN protein downregulation (Fig. 
1C) occurred at the RAS peak, but after Plin2 
induction, and persisted during lipid 
disappearance. PTEN reduction may hence be 
associated with RAS turnover but not with its 
accumulation.  
To estimate PTEN's function during LR, we 
simulated elevated PTEN activity through the 
inhibition of PI3K. Injection of wortmannin 
(0.75mg/kg) at 13h post PH led to reduced 
mitoses, a reduced hepatocyte size (however 
only if lipid vesicles were excluded from 
hepatocyte area), but an increased liver-to-body-
weight-ratio (Lw/Bw) at 48h. The latter was 
likely due to lipid accumulation, which was 
strongly elevated compared to vehicle controls 
(Fig. 1D).  
When PTEN was inhibited by bpV (3.3mg/kg) at 
13h post PH, Lw/Bw and hepatocyte size were 
increased, while RAS was diminished (Fig. 1E). 
Notably, mitotic counts were also reduced 
through bpV, suggesting that PTEN inhibition 
during LR specifically affects the 
phosphoinositide-dependent AKT-mTOR axis, 
which promotes hypertrophy at the expense of 
hyperplasia.14 In contrast, PI3K inhibition 
additionally affects phosphoinositide-
independent STAT3 activation, hence impacting 
on both hyperplasia and hypertrophy.14 Taken 
together, these findings indicate PTEN 
downregulation is associated with RAS turnover, 
weight regain, and hypertrophy in regenerating 
liver.  
Hepatocyte-specific Pten deficiency accelerates 
functional liver recovery via hypertrophy  
PTEN inhibition after hepatectomy promotes 
liver weight recovery, however bpV acts 
systemically and may exert unspecific effects. 
We therefore used inducible hepatocyte-specific 
Pten knockout mice to define the impact of 
PTEN deficiency on LR. Knockout was induced 
by TAM in AlbCreERT2tg/+-Ptenfl/fl (PtenKO) 4d 
prior to hepatectomy to avoid pre-existing fatty 
liver that may impair regenerative capacity.22 
AlbCreERT2+/+-Ptenfl/fl lacking Cre served as 
controls (PtenC). Pten expression was not 
significantly altered after PH in PtenC (Fig. 2A), 
suggesting PTEN downregulation (Fig. 1C) is 
regulated posttranscriptionally following 
resection. Regenerated livers in PtenKO mice 
remained Pten deficient, reflecting liver 
reconstitution from differentiated (albumin-
positive) hepatocytes (Fig. 2A).  
At PH, the starting weight of the liver remnant 
was slightly increased in PtenKO relative to 
PtenC. After PH, the difference in liver weight 
became more pronounced over time, leading to 
hepatomegaly in PtenKO after a week (Fig. 2A). 
Notably, accelerated weight gain was not 
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associated with proliferation (Fig. 2B; Suppl. 
Fig. 1), but with enhanced hepatocellular 
hypertrophy (Fig. 2C).  
To determine whether accelerated weight gain 
leads to improved liver recovery, we performed 
91%-hepatectomy, which causes lethal liver 
failure in wt mice.20 The best measure to assess 
recovery of liver function is seven-day-survival, 
the critical period after liver loss. Remarkably, 
survival was raised to 40% after 91%-resection 
in PtenKO mice (Fig. 2D), indicating that the 
surplus hypertrophic liver mass generated by 
PTEN deficiency is functional.   
Given the significant hypertrophy at 72h post 
PH in PtenKO, we investigated AKT-mTOR-
S6K signaling, known to promote a hyperplasia-
to-hypertrophy switch.14 Activating AKT 
phosphorylation was markedly increased by 
PTEN deficiency (Fig. 2E). Likewise, enhanced 
S6K phosphorylation indicated elevated 
mTORC1 activity. Increased phosphorylation of 
AKT and S6K was also evident at 32h (Suppl. 
Fig. 2), consistent with AKT-mTORC1-S6K 
signaling as a hypertrophic driver in 
regenerating liver from PtenKO.  
Pten deficiency promotes glucose storage and 
lipid metabolism in regenerating liver 
Acceleration of liver regeneration in PtenKO is 
expected to rely on additional energy supply. We 
hence assessed hepatic energy stores, mainly 
consisting of triglycerides (TGs) and glycogen.  
Following hepatectomy, both PtenKO and PtenC 
displayed early drops in liver glycogen and 
serum glucose (Fig. 3A), a reported signal 
required for the initiation of regeneration.4 
Notably, glycogen stores recovered faster in 
PtenKO relative to PtenC, accompanied by 
downregulation of gluconeogenic expression 
(Ppargc1a, Pck1, G6pc; Fig. 3A). Given the 
similar serum glucose levels, these findings 
indicate PTEN deficiency counteracts glucose 
usage in regenerating liver.  
Hepatic TG content was elevated in PtenKO at 
hepatectomy and peaked at 16h akin to PtenC 
(Fig. 3B; see Supplementary Fig. 3 for chemical 
fat analysis). The subsequent decline in TG 
levels was delayed in PtenKO relative to PtenC. 
Therefore, the loss of PTEN prior to 
hepatectomy leads to an expanded RAS period. 
In contrast, inhibition of PTEN at the RAS peak 
shortened this period (Fig. 1E), suggesting 
PTEN deficiency does not directly enhance RAS 
formation during LR. An expanded RAS period 
may hence be secondary to the increased 
hepatoperipheral lipid shuttle pre-existing in 
PtenKO before PH.11 Accordingly, serum TGs 
were elevated in PtenKO at PH, but dropped 
during the RAS peak similar to PtenC (Fig. 3B). 
Likewise, serum levels of HDL - transporting 
TGs into liver - were increased in PtenKO 
versus PtenC during LR (Fig. 3B).  
Moreover, the expression of Lipe and Lpl - 
lipases that free fatty acids from TGs23,24 - was 
elevated in PtenKO (Fig. 3B). On the other 
hand, Plin2 and Cd36 expression was unaffected 
by PTEN knockout (Supplementary Fig. 3), 
again suggesting PTEN deficiency does not 
directly promote RAS formation in regenerating 
liver (Fig. 1A/C). Accordingly, expression of 
Fabp4 - required for hepatocyte-adipocyte 
transdifferentiation and upregulated in resting 
PtenKO liver12 - was not enhanced and even 
downregulated by PTEN loss during the RAS 
period (Supplementary Fig. 3).  
The changes in lipid content further suggest that 
hypertrophy in PtenKO is not due to fat 
elevations, because at 72h the gains in 
hypertrophy and Lw/Bw were marked (Fig. 
2A/C) despite a minimal lipid content (Fig. 3B, 
Supplementary Fig. 3). Hypertrophy may hence 
relate to the elevated glycogen content (Fig. 3A) 
in regenerating PtenKO liver.  
Besides peripheral fat import, resting PtenKO 
liver is known to accumulate fat also via 
increased lipid synthesis.11 Accordingly, 
lipogenic molecules (SREBP1 and its 
transcriptional targets Scd1, Fasn) were 
upregulated at hepatectomy in PtenKO liver 
remnants (Fig. 3C). After hepatectomy, 
however, the lipogenic program was suppressed 
(Fig. 3C), indicating little contribution of hepatic 
lipogenesis to RAS.  
Finally, we assessed the expression of Fgf21, a 
catabolic molecule shown in the liver to inhibit 
lipogenesis but promote glycogenesis and lipid 
oxidation.25,26 In both PtenKO and PtenC, Fgf21 
expression peaked with RAS. In PtenKO, a 
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second peak was present around 48h post PH 
(Fig. 3D), implying a prolonged catabolic phase 
perhaps related to the extended period of RAS 
and its disappearance at 72h in the mutant 
animals.  
Altogether, these results suggest that the 
expanded RAS period in PtenKO results neither 
from increased lipogenesis nor from elevations 
in active lipid import. Rather, the systemic 
redistribution of lipids into liver after tissue 
loss4,27 may be enhanced due to an elevated 
mobilization of peripheral fats pre-existing in 
PtenKO liver before PH,11,12 and perhaps 
because of a higher catabolism of lipids within 
the liver.  
Pten deficiency promotes lipid oxidation as an 
energy source after hepatectomy 
To gain insight into concrete metabolic outputs 
during LR and the effects of PTEN loss 
thereupon, we measured RER (respiratory 
exchange ratio CO2/O2) after PH via indirect 
calorimetry. The typical diurnal shift towards 
lipid oxidation was recorded for both PtenKO 
and PtenC (Fig. 4; see Supplementary Fig. 4 for 
control data). On resection, RER markedly 
dropped during the first 32h, identifying lipid 
oxidation as the favored energy source during 
the RAS period of regenerating liver. Unlike for 
PtenC, RER around the RAS peak remained 
close to 0.7 in PtenKO, indicating pronounced 
fat catabolism when PTEN is low. From 32h 
onwards, RER began to rise towards pre-
hepatectomy levels. Another reduction in RER 
was recorded in the mutant animals towards 72h, 
thus before TGs were disappearing in PtenKO 
liver. Therefore, LR leads to a profound increase 
in global lipid oxidation, which is enhanced 
through hepatic PTEN downregulation and 
correlates with the disappearance of liver fat.  
Pten deficiency fuels hypertrophic LR via β-
oxidation of RAS-derived lipids 
The increases in lipid oxidation seen in PtenKO 
animals after hepatectomy may originate from 
the metabolism of RAS lipids to fuel the 
regenerative process. When assessing Fabp2, 
needed for import of fatty acids into and their 
oxidation within mitochondria, its expression 
was consistently increased in regenerating 
PtenKO compared to PtenC liver. Moreover, 
CPT1A, the key β-oxidation enzyme, was 
upregulated at the RAS peak in PtenKO liver 
(Fig. 5A).  
If RAS lipids are oxidized in mitochondria to 
provide energy for liver growth, inhibition of β-
oxidation should result in persisting steatosis 
and a diminished liver weight after hepatectomy. 
We first tested siRNA knockdown of Cpt1a 
using a formulation preferentially targeting 
hepatocytes.20 While efficient Cpt1a knockdown 
was achieved in liver, CPT1A protein was not 
affected (data not shown), perhaps owing to a 
long half-life ongoing with its vital function.28 
Instead we treated animals with the CPT1 
inhibitor etomoxir. High doses (20mg/kg) given 
16h after resection led to rapid death of animals, 
likely due to the systemic action of etomoxir on 
all CPT1 isoforms in tissues such as the heart. 
When applying lower doses (10mg/kg) every 
12h starting at 16h post PH, mice survived and 
tissue could be analyzed. At 72h after PH - when 
liver is lean and PtenKO display hypertrophy 
with elevated liver weight - etomoxir did not 
significantly alter Lw/Bw or hepatocyte size in 
PtenC relative to vehicle controls, despite a mild 
increase in hepatic lipids (Fig. 5B). The lack of 
distinct effects may not only relate to the low 
dose but also to the fact that etomoxir will not 
inhibit the oxidation of medium and short chain 
fatty acids. In PtenKO however, etomoxir 
reduced liver weight while markedly increasing 
the hepatic TG content. Moreover, hepatocyte 
size of PtenKO was diminished by etomoxir and 
no more different from that of PtenC 
hepatocytes (Fig. 5B). Therefore, mild inhibition 
of β-oxidation does counteract the hypertrophic 
parenchymal growth driven by PTEN loss, 
however it appears insufficient to impact on the 
general regeneration process. We conclude that 
RAS provides lipids for β-oxidation to fuel 
hypertrophic LR, a process promoted by PTEN 
downregulation.  
mTOR mediates PTEN loss-driven hypertrophy 
in regenerating liver 
Both AKT and mTORC1-S6K have been 
implicated in the regulation of hepatocellular 
hypertrophy.4 The activities of both AKT and 
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mTORC1-S6K were elevated in PtenKO relative 
to controls (Fig. 2E, Supplementary Fig. 2). To 
reveal contributions of these molecules to the 
processes driven by PTEN loss, we treated 
PtenKO and PtenC with moderate doses of the 
specific mTORC1 inhibitor rapamycin, injecting 
1mg/kg at 13h post PH and subsequently every 
24h until harvest. In PtenC at 72h post resection, 
rapamycin had little effect on liver weight, the 
reduction of hepatocyte size, and the hepatic TG 
content relative to vehicle controls (Fig. 6). In 
PtenKO, rapamycin significantly reduced liver 
weight and hepatocyte size, but did not 
significantly impact on TG content. These 
findings portray mTOR is a major promoter of 
hypertrophy in Pten loss-driven regeneration, 
while lipid metabolism may preferably be 
regulated also via mTOR-independent paths in 
regenerating liver.  
 
Discussion 
 
Transient steatosis occurs in every regenerating 
liver and meanwhile is recognized as an 
essential component of successful recovery after 
tissue loss. The precise function of RAS has 
remained unknown thus far, however the 
delivery of energy for the regenerative process 
provides a conceivable explanation. Here, we 
show that the tumor suppressor PTEN 
participates in liver regeneration (LR), with its 
downregulation promoting liver growth fueled 
by RAS. More specifically, we demonstrate that 
(i) RAS turnover is associated with the 
downregulation of PTEN after PH; (ii) PTEN 
deficiency promotes AKT-mTORC1 signaling 
and hypertrophic liver growth; and (iii) β-
oxidation of RAS-derived lipids is required for 
hypertrophy driven by PTEN deficiency. 
Moreover, our data indicate a general shift to 
lipid oxidation during LR, consistent with the 
view that the burning of fat is a main energy 
source for the regenerative process.   
Following PH, PTEN is downregulated at a time 
when lipid accumulation peaks in regenerating 
liver. Our initial experiments using wortmannin 
and bpV suggested PTEN regulates hypertrophic 
liver growth in association with RAS turnover. 
To better appreciate the function of PTEN 
downregulation, we explored regeneration in 
liver with hepatocyte-specific PTEN loss.  
In quiescent liver, the loss of PTEN causes 
pathological steatosis developing from elevated 
lipogenesis and an increased import of 
peripheral lipids, likely related to exaggerated 
insulin-PI3K-AKT signaling.11-13 In regenerating 
liver, Pten loss had a different outcome. 
Although Pten loss was associated with an 
expanded RAS period, it had no impact on 
molecules that are upregulated in resting 
PtenKO liver to promote lipid accumulation (i.e. 
import, vesicle formation, lipogenesis) - in 
keeping with PTEN's role in normal 
regenerating liver, where RAS formation 
occurred prior to PTEN downregulation. These 
observations are remarkable inasmuch as they 
illustrate how after tissue loss the regenerative 
program dominates over other processes, 
adapting the function of PTEN (and likely other 
molecules) for its own purposes.  
While PTEN deficiency in resting liver mainly 
promotes energy storage, our studies on 
regenerating liver reveal a catabolic function for 
PTEN downregulation. Calorimetric 
measurements demonstrated a clear shift 
towards lipid consumption during the RAS 
period in PtenC. This shift was accentuated in 
PtenKO and preceded the disappearance of 
hepatic TGs after PH. Lipid oxidation was 
accompanied by an elevation in β-oxidation 
molecules and a reduction in glucose utilization 
in regenerating PtenKO liver, emphasizing fat as 
a preferred energy source. Therefore, PTEN 
downregulation after hepatectomy appears to 
foster a unique phenotype in that it promotes 
lipid oxidation while enhancing glucose storage.  
Although mild inhibition of long chain fatty acid 
oxidation had no effect on liver growth in wt 
mice, the marked calorimetric shift towards lipid 
oxidation after PH also in PtenC - together with 
the upregulation of β-oxidation genes in wt mice 
- strongly suggests that RAS serves as a general 
provider of energy for regenerating liver. 
Previous research is fully consistent with this 
view; in 2004, Shteyer et al. showed that the 
inhibition of RAS through either leptin or the 
deletion of hepatic glucocorticoid receptors 
suppresses regeneration after PH.5 Although the 
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relevance of RAS was questioned in a 
subsequent study,29 mounting evidence from 
various approaches consistently points to RAS 
as crucial for successful regeneration. 
Accordingly, counteracting peripheral fat 
mobilization prior to PH is sufficient to prevent 
RAS and to inhibit regeneration, with depletion 
of peripheral fat stores being proportional to the 
lost volume.6,7 Besides interfering with 
peripheral fat import, deficient regeneration is 
likewise induced through a variety of other 
measures that counteract RAS formation, 
including β-glucosylceramide pretreatment,30 
knockout of Plin2 (impaired lipid vesicle 
formation),21 or Tm7sf2 deletion (defective 
cholesterol biosynthesis).31 Additionally, animal 
models associated with deficient β-oxidation - 
such as due to knockout of adiponectin or other 
molecules regulating energy usage - present with 
deficient regeneration and persisting RAS.32-35 
Finally, earlier experiments with the β-oxidation 
inhibitor octanoylcarnitine pointed to lipids as 
the dominant energy source early after PH.36  
Importantly, in both models of PTEN deficiency, 
liver weight and hepatocyte size were increased 
at times when TG content was close to nil (i.e. 
bpV 48h, PtenKO 72h), linking PTEN 
deficiency, RAS turnover and hypertrophic liver 
growth. When β-oxidation was mildly inhibited 
from the RAS peak onwards, hepatic TGs 
remained elevated at 72h in PtenKO, ongoing 
with a reduction in liver weight and hepatocyte 
size. Overall, these findings identify RAS as a 
source of lipids that are being oxidized to fuel 
hypertrophic liver growth in a PTEN-dependent 
manner (Fig. 7).  
Our observation of PTEN downregulation as a 
promoter of hypertrophic LR is not unexpected. 
PTEN deficiency occurs in various hypertrophic 
pathologies, and cell type-specific Pten loss may 
be etiological in diseases such as cerebellar 
hypertrophy,37 macrocephaly,38 or hypertrophic 
cardiomyopathy.39 Notably, the hypertrophic 
changes in animal models of above diseases can 
be corrected by the inhibition of mTORC1.37-39 
Similarly, moderate dose rapamycin treatment of 
PtenKO during the RAS peak inhibited both 
hepatocellular hypertrophy and the excess liver 
weight gain, consistent with the PDK1-AKT-
mTORC1 axis as a promoter of hypertrophic 
regeneration.14 Whether rapamycin may 
specifically affect mTORC1 or also mTORC2 in 
liver is a matter of debate.40,41 In any case, our 
observation is consistent with mTOR as a central 
regulator of cell size.42 Recent findings indicate 
that mTORC1-S6K can promote Cpt1a 
expression and lipid oxidation in resting liver.19 
However, rapamycin did not increase TG 
content in regenerating liver, suggesting either 
incomplete inhibition or a metabolism of RAS-
lipids by other molecules regulated through 
PTEN.  
AKT is known to directly regulate hepatic lipid 
metabolism, however the outcomes appear to be 
context-dependent. Established is AKT's role in 
fostering lipid accumulation, via promoting 
SREBP-dependent lipogenesis43 and via 
suppression of β-oxidation.44,45 Conversely, 
AKT seems to promote lipid turnover in other 
situations, such as in ACE2-mediated 
amelioration of fatty liver disease.46 The 
antisteatotic properties of exercise have also 
been related to the upregulation of AKT.47 
Perhaps most fascinating is the association of 
AKT activity with increased hepatic lipid 
oxidation and oxidative capacity triggered by 
calorie restriction.48 Fasting provokes 
hypoglycemia, glycogen depletion, mobilization 
of peripheral fats and a switch to lipid usage,49 
thus processes that we also observe in 
regenerating liver. Intriguingly, hepatocyte-
specific deletion of Sirt1, a key energy sensor 
activated through nutritional deprivation, causes 
deficient liver regeneration accompanied by 
persisting RAS and a failure to upregulate genes 
needed for lipid oxidation.35 More so, insulin 
levels drop upon fasting, while in regenerating 
liver insulin responsiveness appears to be 
dampened.50 In terms of energy changes, the 
instant events occurring after hepatic tissue loss 
may hence be comparable to the early response 
towards acute fasting, albeit coupled to the 
specific demands of a growing tissue. The 
reduced insulin responsiveness further suggests 
AKT activation after PH occurs independent of 
insulin, perhaps explaining the divergent 
outcomes (i.e. fat storage versus usage) of AKT-
mTOR signaling in resting (with overactive 
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insulin signaling) versus regenerating PtenKO 
liver.  
The contribution of hypertrophy to liver 
regeneration is being increasingly 
appreciated.51,52 Indeed, the promotion of 
hypertrophic liver growth through PTEN 
downregulation might be of clinical relevance. 
The most frequent cause of death due to liver 
surgery is the small-for-size syndrome (SFSS). 
This clinical entity can develop following too 
extended resection, leaving behind marginal 
remnants that fail to recover due to deficient 
regeneration.3,20 Intriguingly, a consistent feature 
of SFSS livers is persisting hypersteatosis, 
illustrating the intimate relationship between 
RAS and successful recovery. No treatment 
currently exists for this entity, however 
experimental approaches that prevent the SFSS 
also normalize RAS.20 Indeed, PTEN knockout 
was able to rescue 40% of mice after 91% 
hepatectomy, a lethal mouse model of the 
SFSS.20 Therefore, transient inhibition of PTEN 
- such as through bpV - may offer new avenues 
to prevent or treat the SFSS. Moreover, the 
promotion of lipid oxidation may aid such 
measures, as suggested by the impact of lipid-
plus-carnitine infusion on regeneration in rats.53 
In summary, our study highlights the function of 
PTEN in compensatory liver hypertrophy and 
emphasizes the importance of RAS for the 
regenerative process. Following PH, the 
reductions in PTEN have two major 
consequences, that is the promotion of cellular 
hypertrophy via mTOR along with the 
enhancement of β-oxidation - a process that 
appears to be independent of mTOR but 
provides the fuel for the hypertrophic expansion 
of functional parenchyme. The catabolic 
properties of PTEN downregulation enhance the 
turnover of RAS, which forms as a part of the 
metabolic adaptations imposed by the loss of 
liver tissue. More broadly, our findings affirm 
RAS as an obligate component of successful 
liver regeneration, with fat as the prime 
regenerative fuel during the periods of low 
hepatic capacity. The appreciation of lipid 
catabolism in liver regeneration may point to 
novel options for the management of 
regenerative deficiencies in the clinic, such as 
experienced in surgery-induced liver failure.   
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Figures 
 
 
 
 
 
 
 
 
Figure 1. Association between RAS, PTEN and liver regeneration in wt mice. (A) Lipid accumulation 
(HE and Oil RedO stains) after sham surgery or resection. Hepatic Plin2 expression is shown to the 
right. (B) Hepatic gene expression for Cd36 (lipid import), Cpt1a, Hadha, Hadhb (β-oxidation), and 
Scd1, Acaca, Fasn (lipogenesis). (C) Quantified immunoblots for PTEN levels after surgery. (D) 
Wortmannin ("high" PTEN activity) and (E) bpV ("low" PTEN activity) effects on histological RAS, 
hepatic TGs, LWBW regain, mitoses and hepatocyte size at 48h after PH. n≥5/group for mean±SD; 
*P<0.05.  
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Figure 2. Promotion of liver regeneration through hepatic Pten loss. (A) Pten expression and Lw/Bw 
following tamoxifen-treatment and PH in PtenKO and PtenC (control) mice. (B) Mitotic counts and 
cyclin B2 gene expression. Ki67 and pH3 stains of PtenKO/PtenC liver post PH are shown to the right. 
See also Supplementary Fig. 1. (C) Hepatocyte size after resection on histology (left) and by cytometry 
(right). (D) Seven-day survival after lethal 91% PH in PtenKO and controls. (E) AKT-mTOR 
signaling in PtenKO/C assessed by immunoblots 72h after PH. n≥5/group for mean±SD; *P<0.05. 
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Figure 3. Glucose and lipid metabolism in PtenKO and PtenC after PH. (A) Hepatic glycogen content, 
serum glucose and hepatic expression of gluconeogenic genes (Ppargc1a, Pck1, G6pc). (B) Hepatic 
and serum TG levels, serum HDL, and hepatic expression of the genes encoding lipases LIPE and 
LPL. (C) Immunochemistry for the transcription factor SREBP1 and gene expression of its lipogenic 
targets Scd1 and Fasn. (D) Hepatic gene expression of Fgf21. n≥5/group for mean±SD; *P<0.05.  
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Figure 4. Bodily substrate usage in regenerating PtenKO and PtenC mice. Indirect calorimetry via 
metabolic cage measurements of RER before and after PH. n=5/group for mean ±SEM; *P<0.05.  
 
 
Figure 5. β-oxidation associates hypertrophy with RAS in regenerating PtenKO liver. (A) Fabp2 gene 
expression and CPT1A protein expression in PtenKO/C at the RAS peak. (B) Impact of low dose 
etomoxir on Lw/Bw, hepatocyte size and RAS (histology, TG content) in PtenKO/C at 72h port PH. 
n≥5/group for mean±SD; *P<0.05.  
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Figure 6. Dependency of hypertrophy but not lipid oxidation on mTOR in PtenKO. Effects of 
rapamycin treatment during RAS on Lw/Bw, hepatocyte size, and hepatic TG content in PtenKO and 
PtenC at 72h after PH. n≥5/group for mean±SD; *P<0.05.  
 
 
 
 
Figure 7. Model for the function of PTEN downregulation after hepatectomy. The hypoglycemia 
developing with resection triggers the mobilization of adipose stores to redistribute fats from the 
periphery into the liver. PTEN downregulation occurs with the peak of hepatocellular lipid 
accumulation. The resulting enhancement of AKT-mTOR signaling promotes β-oxidation and cellular 
hypertrophy, which is fed through the catabolism of RAS-derived lipids. To facilitate lipid usage, 
PTEN downregulation enhances the expression of lipases to free fatty acids (FFA) from triglycerides 
(TG) and increases the levels of molecules needed for the transport of FFAs into mitochondria. 
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Supplementary Materials 
Supplementary methods 
Water content 
Weighed livers (approx.100mg) were incubated at 1000C. After 24 hours, dry liver remnant weight 
was recorded and the ratio (% dry/total weight) was calculated.  
Protein content 
The DCTM Protein Assay (Biorad, Hercules, CA) was used to quantify protein content (mg/g tissue) of 
liver samples. 
Chemical lipid content 
Liver fat was chemically quantified by the Vanillin method according to Van Handel E. (J Am Mosq 
Control Assoc. 1985;1:302–304) 
 
Supplementary Tables 
Table S1. Antibodies for immunoblots and immunohistochemistry 
antigene company/order no. dilution Pten Cell Signaling, 9559S 1:1000 (WB) pAkt1/2 (Ser473) Cell Signaling, 9271S 1:1000 (WB) pAkt (Thr308) Cell Signaling, 9275S 1:1000 (WB) tAkt Cell Signaling, 9272S 1:1000 (WB) pAkt2 (Ser474) Cell Signaling, 8599S 1:1000 (WB) Akt2 Cell Signaling, 3063S 1:1000 (WB) pS6K Cell Signaling, 4267S 1:1000 (WB) S6K Cell Signaling, 4267S 1:1000 (WB) p4EBP Cell Signaling, 2855S 1:1000 (WB) 4EBP Cell Signaling, 9644S 1:1000 (WB) Rictor Cell Signaling, 2114S 1:1000 (WB) Raptor Cell Signaling, 2280S 1:1000 (WB) Gapdh Cell Signaling, 5174S 1:1000 (WB) HRP-linked anti-rabbit Cell Signaling, 7074S 1:2000 (WB) HRP-linked anti-mouse Cell Signaling, 7076s 1:2000 (WB) Srebp1 Novus Biologicals, NB100-2215 1:500 (IHC) Ki67 Abcam, ab16667 1:200 (IHC) pH3 Millipore, 06-570 1:500 (IHC) 
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Table S2. Taqman gene expression assays  
gene 
name 
Applied Biosystems order no.  
Ccna2 Mm00438063_m1 
Ccnb2 Mm01171453_m1 
Ccnd1  Mm00432359_m1 
Ccne1  Mm00432367_m1 
Cd36  Mm01135198_m1 
Cpt1a  Mm01231183_m1 
Fabp2  Mm00433188_m1 
Fabp4 Mm00445878_m1 
Fasn  Mm00662319_m1 
Fgf21  Mm00840165_g1 
G6pc  Mm00839363_m1 
Hadha  Mm00805228_m1 
Hadhb  Mm01217745_m1 
Lipe  Mm00495359_m1 
LPL  Mm00434764_m1 
Pck1  Mm01247058_m1 
Plin2  Mm00475794_m1 
Ppargc1a  Mm01208835_m1 
Pten  Mm00477208_m1 
Scd1  Mm00772290_m1 18S rRNA TaqMan control reagents 
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Supplementary Figures 
 
Figure S1. Proliferative parameters in PtenKO and PtenC after PH. A trend towards reduced Ki67 
counts was observed in PtenKO from 32h (S phase peak) onwards, suggesting reduced progression to 
and from the S phase. Total pH3 counts (marking G2 or M phase cells) were reduced already around 
the S phase peak, and bold pH3 counts (M phase cells) are reduced around the mitotic peak, again 
suggesting reduced cell cycle progression. Entry into but reduced progression through the cell cycle is 
consistent with an elevation of cellular hypertrophy in PtenKO. At 72h after PH (when TG content is 
close to nil), hepatic water content was similar in both genotypes. 
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Figure S2. AKT-MTOR signaling in PtenKO/PtenC assessed by immunoblots 32h after PH. PtenKO 
liver displayed increased phosphorylation of AKT and S6K, indicating upregulated AKT-MTOR 
signaling at 32h after PH.  
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Figure S3. Lipid content, Cd36 expression and Plin2 expression in PtenKO and PtenC liver after PH. 
The assessment of lipid content via the vanillin methodology mirrored the changes in hepatic TGs after 
PH. Plin2 and Cd36 expression were similar in PtenKO and PtenC during the regenerative phase, 
suggesting PtenKO has little impact on lipid import and vesicle formation. Towards the end of 
regeneration (1 week) however, lipid content and Cd36 expression began to rise (with Plin2 displaying 
an nonsignificant increase) in knockouts, consistent with the phenotype reported for resting PtenKO 
liver.  
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Figure S4. Assessment of food intake, heat production, movement and body composition (fat versus 
lean mass) in PtenKO and PtenC mice after PH. Data was retrieved from individual mice kept in 
metabolic cages. No significant differences between the two genotypes were observed. 
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6. Discussion 
The metabolic adaptations that occur immediately after hepatic resection were among the first 
changes reported for the regenerating liver.  
Initially, hypoglycemia and the subsequent accumulation of hepatic lipids were not considered to be of 
functional relevance, but rather a consequence of deficient liver function. However, growing piles of 
experimental evidence point to the contrary. Eventually, Rudnick and Davidson summarized these 
novel insights in a review entitled “Metabolic theory of liver regeneration.” In its essence, their 
message was that the metabolic insufficiencies caused by acute tissue loss have a role in the initiation 
of liver regeneration [LR], which is equal to that of growth factors, cytokines and other pro-
regenerative pathways [89]. 
During the past few years my main interest was directed towards LR-associated metabolism. For my 
thesis, I wished to explore (i) how diminished metabolic function of the liver is translated into 
regenerative signals; and (ii) whether regeneration associated steatosis [RAS] as a metabolic response 
to hepatic insufficiency is providing energy for tissue recovery. 
In brief, my research revealed the following main findings: 
- CAR after resection promotes liver function through its metabolic activities (such as bilirubin 
clearance) and the parallel induction of pro-regenerative molecules, in particular FOXM1. In resection-
induced liver failure, CAR activation is deficient and associated with both metabolic and proliferative 
deficiencies. Reactivation of CAR normalizes all deficiencies in a way dependent on FOXM1, 
emphasizing that regrowth of liver mass is essential to maintain metabolic capacity. 
- After 70% hepatectomy, PTEN is downregulated to promote beta-oxidation of RAS-derived 
lipids, thereby providing energy for AKT-mTORC1-driven hypertrophy. 
Further to the elucidations in our manuscripts, I would like to discuss some more aspects of my work I 
deem relevant. 
6.1 Multiple aspects of CAR action during liver regeneration 
The clinical potential of CAR activators was extensively discussed in “Manuscript B”. Here I would like 
to concentrate on the diverse molecular mechanisms which are induced through CAR and result in 
accelerated LR or even can rescue from the small-for-size syndrome [SFSS].  
We demonstrated that FOXM1 is necessary for CAR to exhibit its beneficial effect on LR. It is known 
that CAR can activate FOXM1 via MYC [75], however it also was shown that FOXM1 on its own is 
essential for LR itself [32]. Therefore, its knockdown might have obscured FOXM1-independent effects 
of CAR. Moreover, Foxm1 knockdown did not completely abrogate all effects of CAR activation, 
providing alternate evidence for FOXM1-independent pathways regulated through CAR during LR.  
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As already mentioned in the thesis introduction, CAR is known to affect liver growth also through 
molecules other than MYC/FOXM1 (see Fig. 3 in the introduction). For example, CAR can stimulate the 
expression of cyclin D directly, thereby promoting also cell cycle entry. Notably, livers following 
extended hepatectomy exhibit higher expression of cyclin D vs 70% hepactectomy ([63] and data not 
shown). However, the induction of cyclin D is unlikely to account for the preventive and/or rescuing 
effects CAR activation had in our SFSS mouse model. The prime defect behind SFSS development is a 
delay in the progression through the S and M phases; accordingly, we observe reduced cyclin A and B 
expression after extended hepatectomy relative to standard 70% hepatectomy. Indeed, cyclin D 
expression is increased after extended hepatectomy, and so are Ki67 counts (i.e. counts of 
hepatocytes that have entered the cell cycle after resection). It therefore seems that cyclin D is more 
important for CAR-induced spontaneous hepatomegaly than for the prevention of the SFSS.  
On the other hand, CAR has been shown to increase YAP1 activities in the liver [114]. Intriguingly, our 
preliminary data indicate a deficient induction of YAP1 in the SFSS, which can be normalized through 
CAR re-activation. Further to this, our data suggest that YAP1 is important for the entry of hepatocytes 
into the cycle, but also for their further progression to the S phase. We hence believe that the benefits 
of CAR activation in the SFSS may to some part also rely on the promotion of YAP1 activity after 
resection.  
Finally, CAR can repress P21 not only via FOXM1 or YAP1-dependent mechanisms, but also through 
the direct inhibition of the Cdkn1a transcriptional promoter FOXO1 [112]. Given that deletion of P21 
mitigates most abnormalities associated with the SFSS [63], the direct effects of CAR on P21 are 
expected to add to the promotion of regeneration in resection-induced liver failure.   
6.2 PTEN and steatosis in liver surgery 
In the “Manuscript A” covering PTEN's function in LR we discussed potential molecular mechanisms 
that may mediate the effects elicited through PTEN downregulation. Further to this, I would like to 
discuss the broader relevance of these findings in clinical settings, particularly with regards to 
pathological steatosis.   
Severe pre-existing steatosis has been identified as a significant risk factor for postoperative 
complications including liver failure. In both cadaveric and living donor liver transplantation, grafts 
with severe or moderate steatosis (>30%) are excluded [135]. Likewise, liver resection is considered to 
be safe only if the degree of steatosis does not exceed 30% [136].  
Steatotic liver is highly sensitive towards ischemic injury (often an obligate component of liver surgery) 
and has a diminished capacity to regenerate.  The reasons behind these faults are not completely 
clarified, but endothelial dysfunction along with altered mitochondrial capacity and oxidative stress 
are conceivable and accepted causes [137-139]. The options to manage fatty liver disease are rather 
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limited. Apart from exercise, pre-operative steatosis can be improved within a few weeks via a diet low 
in fat but rich in protein [140]. Another promising approach is based on omega-3 fatty acids and is 
currently being trialed in our clinic (NCT01884948). In mouse models, our lab could show that 
treatment of steatotic liver with omega-3 fatty acids ameliorates hepatic ischemia reperfusion injury 
and accelerates regeneration via both antisteatotic and steatosis-independent effects [141].  
Intriguingly however, others have reported that mild pre-existing steatosis has little or even a 
beneficial impact on liver regeneration [142, 143]. Such findings suggest that steatosis may be harmful 
only if above a certain threshold. Additional research is hence needed to define the degree of 
steatosis, but also the extent of associated changes (e.g. inflammation, lipotoxicity, microcirculation) 
below which surgery is safe. On the other hand, our findings together with those from several previous 
studies indicate that the acute development of steatosis after resection is a phase essential for the 
regenerative process [76, 86, 87]. Our calorimetric measurements demonstrated a clear shift towards 
the use of lipids as a primary energy source in the initial stage of regeneration. The shift to lipid usage 
correlated with PTEN downregulation after hepatectomy and was pronounced in our Pten knockout 
animals.  The requirement of fat for liver to regenerate hence explains why mild pre-existing steatosis 
can promote regeneration. If steatosis however is marked, it starts to impair sinusoidal function and 
perfusion, which have key roles in the recovery of liver mass.   
The loss of PTEN in liver is known to cause steatosis [123, 124]. We induced liver-specific Pten 
knockout a few days before hepatectomy to avoid the development of significant, pre-existing fatty 
liver. Despite this short interval, PtenKO mice presented with very mild steatosis already at 
hepatectomy. Following hepatectomy, PtenKO caused an accelerated liver weight regain. While our 
experiments using the inhibitor etomoxir showed that the promotion of beta-oxidation through PTEN 
loss is the main driver behind enhanced regeneration, it is well possible that the mild pre-existing 
steatosis in PtenKO has aided in this effect.  
Along these lines, another noteworthy observation in our PTEN study is the divergent action of this 
molecule in resting versus regenerating liver. The loss of PTEN in resting liver upregulates lipogenesis, 
fat import (e.g. Cd36), and induces a mild transdifferentiation of hepatocytes towards adipocytes (as 
evinced through the upregulation of adipocyte markers such as Plin2 and Fabp4). In contrast, 
lipogenesis and the expression of Cd36, Plin2 and Fabp4 were similar in PtenKO and PtenC after 
hepatectomy, indicating little effect of the knockout on these parameters in regenerating liver. These 
observations imply that the liver regeneration program is highly dominant over the usual processes 
occurring in resting liver. Thus, the regeneration program appears to adapt PTEN for functions this 
molecule normally does not exert in resting liver. Indeed - at least to our knowledge - this is the first 
study that has associated PTEN downregulation with the catabolism of lipids, in stark contrast to many 
other reports linking PTEN deficiency with the accumulation of lipids [123, 124, 144]. Therefore, the 
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unique role of PTEN in liver regeneration also highlights the biological plasticity that has evolved to 
adapt an organism to acute changes. 
By fostering the beta-oxidation of RAS-derived lipids, PTEN downregulation promotes hypertrophic 
liver growth. In PtenKO, the hypertrophic response is enhanced and leads to hepatomegaly. 
Importantly, this additional liver mass is functional, as demonstrated by the survival raised from 0% in 
controls to 40% in PtenKO after 91%-hepatectomy (a lethal model of resection-induced liver failure 
mimicking the small-for-size syndrome). These results suggest that the transient inhibition of PTEN at 
or after extended resection may be a strategy to improve outcomes of hepatic surgery. Given that 
cancer is the prime indication for extended resection, the risks associated with PTEN inhibition are 
obvious. One of the most mutated tumor suppressors in human cancer [145], the loss of PTEN in 
resting mouse liver leads to the development of steatosis-associated hepatocellular carcinoma over 
time [124]. However, it is currently unclear whether a short-lived, transient inhibition of PTEN is 
sufficient to actually promote residual/occult disease in liver. Moreover, inhibition would occur in 
regenerating liver, where PTEN seems to assume functions different from those in resting liver. 
Clearly, such risks need a careful assessment, but also have to be outweighed against the potential 
benefit of PTEN inhibition, i.e. the rescue from sudden death due to postoperative liver failure - still 
the most frequent cause of death due to liver surgery. Finally, our findings imply that a perioperative 
supply of lipids together with promoters of beta-oxidation (such as carnitine) might aid the successful 
completion of regeneration after extended hepatectomy.   
Concluding remarks: At the end of the discussion, I would like to draw attention to the similarities that 
seem to exist for CAR and PTEN in the regenerating liver. PTEN downregulation after hepatectomy 
promotes liver growth in relation to the suppression of lipogenesis, the oxidation of lipids, and a shift 
from glucose usage to storage. CAR activation after hepatectomy likewise promotes liver growth; 
besides its detoxifying and clearance activities, CAR has further been shown to enhance insulin 
sensitivity and to suppress lipogenesis as well as gluconeogenesis [146, 147]. Whether the latter 
occurs in a CAR-dependent way also in regenerating liver is not known. Nonetheless, the features 
associated with PTEN downregulation and CAR activation point to interesting parallels, that is the 
coupling of growth promoting abilities with the capacity to modulate energy metabolism - features 
that well might predestine these two molecules to play crucial roles in the regrowth of liver.  
Taken together, these two proteins nicely illustrate the reciprocal regulation that occurs between 
tissue growth and its metabolic performance during liver regeneration: PTEN regulates catabolic 
metabolism to promote tissue growth, while CAR accelerates liver growth to promote metabolic 
function.  
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7. Future directions  
YAP1 as a mediator of CAR activities in liver growth 
In manuscript B, we demonstrated that the pro-regenerative effects of CAR are implemented through 
FOXM1. Our results further suggest that other downstream molecules must act to convey the full 
impact of CAR activation on regenerating liver. Our recent, preliminary data indicate that YAP1 as well 
is an effector downstream of activated CAR following hepatectomy. Using a siRNA knockdown 
approach, we are currently working to confirm the role YAP1 appears to have in the CAR-dependent 
network after resection (Fig. 5). We expect that the establishment of YAP1-regulated effects will help 
to cement the central position of CAR in the coordination of different stages during liver recovery. 
 
 
Figure 5. CAR-dependent pathways in the prevention of liver 
failure following tissue loss. After extended hepatectomy and 
TCPOBOP (TCP) administration, CAR promotes cell cycle 
progression through YAP1 and particularly FOXM1. YAP1 mainly 
stimulates progression through G1 and S, associated with 
improvements in albumin production and the exaggerated RAS 
seen in the SFSS. FOXM1 accelerates progression through S and 
M, improving hypoalbuminemia, persistent steatosis and 
hyperbilirubinemia. Hyperbilirubinemia likely is reduced also 
through direct induction of the bilirubin clearance pathway by 
CAR. (Dr. Humar, unpublished) 
 
 
Role of PTEN alterations in liver failure 
Persistent steatosis and deficient regeneration are two of the characteristic features of SFSS liver. The 
generic observation that RAS seems to persist after hepatectomy when liver fails to recover suggests 
that the regenerative delay in the SFSS results in a diminished turnover (e.g. oxidation) of RAS-derived 
lipids and hence to the persistence of RAS. On the other hand, the tenacity of RAS may itself impair the 
regenerative capacity of liver.  
To address this question, the timing/magnitude of RAS formation and disappearance should be 
documented at high resolution for both standard and extended resection, and then compared to the 
onset of regenerative deficits developing with liver failure.  
Furthermore, our current data on PTEN downregulation and associated AKT activation after extended 
hepatectomy are puzzling. Compared to standard hepatectomy, PTEN is equally or even more strongly 
downregulated, yet activating AKT phosphorylation is reduced. Given that the deletion of PTEN before 
hepatectomy accelerates regeneration, the prolonged PTEN downregulation seen in the SFSS is 
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unlikely to lead to a negative feedback that would dampen AKT activities. On the other hand, PTEN is 
normally downregulated at the peak of RAS; its prolonged downregulation in the SFSS may hence 
relate to the persistence of RAS (e.g. in the sense that as long there are lipids to be burned, PTEN will 
remain downregulated to promote their oxidation). Finally, we observed a peculiar downregulation of 
PTEN one hour (but re-elevation again at 4h and 8h followed by the expected drop at 16h, the RAS 
peak) after extended but not standard hepatectomy. Again, a fine-tuned time course will be needed to 
define whether this one-hour-drop is unique to the SFSS or merely shifted in time (e.g. observed 30 
min. or 2h after standard hepatectomy).  
The information about RAS dynamics and corresponding PTEN changes should provide important 
information to define potential time windows for a therapeutic exploitation of transient PTEN 
inhibition against the SFSS.  
 
 
 
 
Figure 6. miR-21 expression profile following 
standard (sHx) and extended (eHx) resection 
 
Molecular mechanisms underlying the function of PTEN in liver regeneration 
Upstream of PTEN: What leads to PTEN downregulation after hepatectomy remains unclear. Several 
reports have proposed regulation of PTEN by microRNAs. For example, the Inhibition of the miR-17~92 
cluster in vivo leads to elevated PTEN levels after hepatectomy. However the cluster itself is 
downregulated after resection and hence cannot explain the reductions in PTEN levels [131]. PTEN 
downregulation through miR-382 has likewise been proposed, but was only documented in 
hepatocellular cell lines [133]. Moreover, PTEN downregulation in regenerating liver was associated 
with miR-21 induction [132]. Although such an association could be documented   in vitro [148], we 
could not substantiate a miR-21-PTEN relationship after hepatectomy. We tested this possibility in two 
systems: (i) we performed hepatectomy in mice with a liver-specific deletion of miR-21, but saw little 
impact on PTEN levels compared to mice with wildtype miR-21; (ii) we measured miR-21 expression 
after standard and extended hepatectomy in wildtype mice, but did not observe an inverse correlation 
between miR-21 and PTEN levels. Indeed, PTEN downregulation was prolonged after extended 
resection, but miR-21 induction was deficient (Fig. 6), disqualifying this microRNA as a PTEN regulator 
during LR. However, we plan to follow up the interesting finding of deficient miR-21 expression in the 
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SFSS, particularly as miR-21 has been assigned a pro-regenerative function in regeneration [149]. The 
identification of non-coding RNAs that controls Pten expression during regeneration would offer new 
options (e.g. miRNA-mimics) to modulate PTEN levels after resection.   
A close relative of miR-21 - namely miR-22 - has been reported to target Pten and to promote 
hypertrophy. Moreover, the analysis of constitutive knockout mice has linked miR-22 deficiency to 
metabolic changes that overlap with the PtenKO phenotype seen in resting liver. To define whether 
miR-22 is a potential PTEN regulator after resection; its expression should be assessed during the 
times of PTEN downregulation after both standard and extended hepatectomy.  We furthermore plan 
to assess PTEN levels in liver of hepatocyte-specific miR-22 knockout mice and their controls to obtain 
functional in vivo evidence for the association between miR-22 and PTEN in regenerating liver.  
PTEN-interacting molecules  
The AKT-mTOR axis is considered as the main pathway under the control of PTEN. However, PTEN 
meanwhile is known to exert many other functions and to directly interact with a variety of proteins 
that may mediate some of its actions. Within the frame of our Sinergia collaboration with the group of 
Michelangelo Foti (University of Geneve), we are currently defining proteins that might interact with 
PTEN in regenerating liver. Following their screens in resting, steatotic and cancerous liver, Foti's 
group has identified several proteins the expression of which is strictly correlated to PTEN alterations 
Most of these proteins have been assigned tumor suppressor or oncogenic function. Currently, 
samples from our regenerating livers are being analysed to reveal whether PTEN may interact with 
these proteins also after tissue loss. Pending on outcomes, functional studies may follow to assign 
functions to candidate proteins. A desired result would be the dissection LR-associated PTEN functions 
to specific interaction partners. Such knowledge might enable us to manipulate liver regeneration 
after extended resection in a more targeted way. For example, one might expect a lowering of 
tumorigenic risks if cellular growth could be enhanced indirectly, such as the targeted promotion of 
PTEN-dependent pathways associated with the catabolism of RAS. However, I have learned in my PhD 
that the road leading to these goals will be long and stony.  
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